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8ABSTRACT 
Background Th e occurrence of occupational chronic solvent encepha-
lopathy (CSE) seems to decrease, but still every year reveals new cases. 
To prevent CSE and early retirement of solvent-exposed workers, actions 
should focus on early CSE detection and diagnosis. Identifying the work 
tasks and solvent exposure associated with high risk for CSE is crucial.
Methods Clinical and exposure data of all the 128 cases diagnosed with 
CSE as an occupational disease in Finland during 1995–2007 was col-
lected from the patient records at the Finnish Institute of Occupational 
Health (FIOH) in Helsinki. Th e data on the number of exposed workers 
in Finland were gathered from the Finnish Job-exposure Matrix (FIN-
JEM) and the number of employed from the national workforce survey. 
We analyzed the work tasks and solvent exposure of CSE patients and 
the ﬁ ndings in brain magnetic resonance imaging (MRI), quantitative 
electroencephalography (QEEG), and event-related potentials (ERP). 
Results Th e annual number of new cases diminished from 18 to 3, and 
the incidence of CSE decreased from 8.6 to 1.2 / million employed 
per year. Th e highest incidence of CSE was in workers with their main 
exposure to aromatic hydrocarbons; during 1995–2006 the incidence 
decreased from 1.2 to 0.3 / 1 000 exposed workers per year. Th e work 
tasks with the highest incidence of CSE were ﬂ oor layers and lacquer-
ers, wooden surface ﬁ nishers, and industrial, metal, or car painters. 
Among 71 CSE patients, brain MRI revealed atrophy or white matter 
hyperintensities or both in 38% of the cases. Atrophy – which was as-
sociated with duration of exposure – was most frequently located in the 
cerebellum and in the frontal or parietal brain areas. QEEG in a group 
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of 47 patients revealed increased power of the theta band in the frontal 
brain area. In a group of 86 patients, the P300 amplitude of auditory 
ERP was decreased, but at individual level, all the amplitude values were 
classiﬁ ed as normal. In 11 CSE patients and 13 age-matched controls, 
ERP elicited by a multimodal paradigm including an auditory, a visual 
detection, and a recognition memory task under single and dual-task 
conditions corroborated the decrease of auditory P300 amplitude in 
CSE patients in single-task condition. In dual-task conditions, the au-
ditory P300 component was, more often in patients than in controls, 
unrecognizable. 
Conclusions Due to the paucity and non-speciﬁ city of the ﬁ ndings, 
brain MRI serves mainly for diﬀ erential diagnostics in CSE. QEEG 
and auditory P300 are insensitive at individual level and not useful 
in the clinical diagnostics of CSE. A multimodal ERP paradigm may, 
however, provide a more sensitive method to diagnose slight cognitive 
disturbances such as CSE. 
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TIIVISTELMÄ
Työperäisen liuotinaineaivosairauden esiintyvyys on viimeisten parin-
kymmenen vuoden aikana selvästi vähentynyt, mutta uusia tapauksia 
todetaan edelleen vuosittain. Liuotinaineaivosairauden ja sen seurauksena 
ennenaikaisen eläköitymisen ennaltaehkäisemiseksi on keskeistä tietää, 
missä työtehtävissä ja mille liuotinaineille altistuttaessa on olemassa ris-
ki sairastua liuotinaineaivosairauteen, jotta oireet voidaan tunnistaa ja 
aivosairaus diagnosoida mahdollisimman varhaisessa vaiheessa.
Väitöskirjassa on selvitetty liuotinaineaivosairauden ilmaantuvuutta 
vuosina 1995–2007 sekä missä työtehtävissä ja mille liuotinaineille 
altistuttaessa liuotinaineaivosairautta esiintyy. Lisäksi selvitettiin, min-
kälaisia muutoksia voidaan todeta aivojen magneettikuvauksessa (MRI), 
kvantitatiivisesti analysoidussa aivosähkökäyrätutkimuksessa (QEEG) 
sekä tapahtumasidonnaisissa jännitevastetutkimuksissa (event-related 
potentials, ERP). 
Tutkimusaineistona oli kaikki 128 Työterveyslaitoksella vuosina 
1995–2007 diagnosoidut liuotinaineaivosairaustapaukset. Kliiniset ja 
altistumistiedot kerättiin potilasasiakirjoista. Työllisten lukumäärä pe-
rustuu Tilastokeskuksen tilastoihin ja liuotinaineille työssään altistuvien 
työntekijöiden lukumäärä FINJEM-tietokantaan. 
Tarkastelujakson 1995–2007 aikana vuosittain diagnosoitujen tapa-
usten määrä väheni 18:sta 3:een ja ilmaantuvuus 8,6:sta 1,2 tapaukseen 
miljoonaa työllistä kohti. Ilmaantuvuus oli suurinta parketti- ja matto-
töissä, huonekalujen ja puusepänteollisuustuotteiden maalaus- ja pinta-
käsittelytöissä sekä teollisuus-, metalli- ja automaalareiden keskuudessa. 
Altistumisen perusteella arvioituna suurin ilmaantuvuus oli työssään 
aromaattisille hiilivedyille altistuvien työntekijöiden keskuudessa. 
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Aivojen magneettikuvaus paljasti 38 %:ssa tutkituista tapauksista 
lievää aivoatroﬁ aa ja/tai poikkeavia muutoksia aivojen valkeassa ainees-
sa. Atroﬁ aa, joka oli yhteydessä liuotinainealtistumisen kestoon, oli 
todettavissa erityisesti pikkuaivojen sekä otsa- ja päälakilohkon alueella. 
QEEG-tutkimuksessa theta-jakson absoluuttinen teho oli potilailla li-
sääntynyt otsalohkon alueella terveisiin verrokkeihin verrattuna. ERP tut-
kimuksessa kuuloärsykkeen aikaansaama P300-jännitevastekomponentin 
amplitudi oli potilailla pienentynyt ryhmätasolla verrattuna terveisiin 
verrokkeihin, mutta yksilötasolla amplitudit jäivät normaalivaihtelun 
rajoihin. Käytettäessä sekä kuulo- että näköärsykettä tehtävän aikana 
(dual-task paradigm) kuuloärsykkeen aikaansaama P300 vaste puuttui 
potilailta selvästi useammin kuin terveiltä verrokeilta.
Aivojen MRI-löydökset olivat lieviä ja epäspesiﬁ siä, minkä vuoksi 
MRI-tutkimus soveltuu lähinnä liuotinaineaivosairauden erotusdiagnos-
tiikkaan. Löydökset QEEG-tutkimuksessa olivat vähäisiä ja epäspesiﬁ siä, 
eikä menetelmää voida suositella liuotinaineaivosairauden kliiniseen 
diagnostiikkaan. ERP-tutkimuksessa käytetyt paradigmat osoittautuivat 
epäherkiksi eivätkä ne sellaisenaan sovellu yksilötason diagnostiikkaan 
vaan vaativat edelleen kehitystyötä. Useamman paradigman yhdistämises-
tä syntyvä ERP-proﬁ ili tai monimuuttujamalli, jossa analysoidaan useita 
jännitevastekomponentteja, saattavat tulevaisuudessa tarjota herkemmän 
menetelmän lievien kognitiivisten häiriöiden, kuten liuotinaineaivosai-
rauden, diagnostiikkaan.
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1.  INTRODUCTION
Th e history of occupational solvent neurotoxicity dates back to the 1850s, 
when the French physician Auguste Delpech reported severe neuropsy-
chiatric symptoms in workers exposed to carbon disulﬁ de in rubber 
manufacture (1,2). Carbon disulﬁ de was one of the ﬁ rst industrial ap-
plications of a group of chemicals referred to as “organic solvents.” In the 
1900s, their industrial use expanded rapidly. Th e acute central nervous 
system (CNS) eﬀ ects of these substances, e.g., unpleasant symptoms of 
dizziness, nausea, and fatigue, were recognized but regarded as reversible 
eﬀ ects without permanent CNS damage (1). 
Evidence for chronic CNS adverse eﬀ ects related to occupational 
solvent exposure began to emerge in the early 1960s when the Finnish 
neuropsychologist Helena Hänninen published a case series of carbon 
disulﬁ de intoxication in rubber manufacturing with chronic CNS eﬀ ects 
at clearly lower exposure levels than in the cases of the 1800s (3). She 
proposed this “psycho-organic syndrome” or “organic solvent syndrome” 
as a new occupational disease. 
Numerous epidemiological and cross-sectional studies have shown 
that long-term occupational exposure to various organic solvents may 
result in irreversible damage to the CNS (4). Th e existence of solvent-
induced chronic toxic encephalopathy (i.e., organic brain disorder), 
also referred to as chronic solvent encephalopathy (CSE), was ﬁ rst 
acknowledged as an occupational disease in Finland, Sweden, Norway, 
and Denmark in the 1970s and in some European countries and the 
United States in the 1980s (2). In 1987, the National Institute for Oc-
cupational Safety and Health (NIOSH) in the United States recognized 
the neurotoxic potential of organic solvents for the human nervous 
system and gave recommendations to focus on occupational exposure 
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levels and hygienic actions (5). Worldwide, CSE is not, however, widely 
accepted as an occupational disease and even in European countries it is 
under-recognized, with national diﬀ erences in the diagnostic procedure, 
litigation, and compensation (2,6,7). Th e present diagnostic criteria 
include substantial long-term exposure to organic neurotoxic solvents 
and typical symptoms together with signs of neurological and cognitive 
dysfunction described later on in this thesis.
Worldwide, millions of workers are occupationally exposed to organic 
solvents. In the United States alone, the estimated number of solvent-
exposed workers is nearly 10 million, which is 3.7% of the general 
population (5,6). Th is corresponds to the estimate from New Zealand 
where around 100 000 workers, or 2.7% of the general population, 
were in the 1990s exposed to organic solvents (6,8). In Finland, in the 
1990s about 50 000, but in the 21st century only 20 000 workers of the 
national workforce of 2.5 million (0.8% of the workforce and 0.4% of 
the general population) were occupationally exposed to organic solvents 
(9). Th e ﬁ gures may be even ten-fold higher with occasional and very 
low-level exposure taken into account. During the last decades, the 
number of exposed workers and solvent exposure in many work tasks 
has diminished due to legislative, technical, and hygienic actions includ-
ing substitution of less harmful water-based chemicals and introduction 
of closed processes (10–12). Th e prevention of solvent-related adverse 
eﬀ ects has been possible in industrialized countries due to legislative ac-
tions and agreements between trade unions and employers (1,13). Th is 
has led to a decrease in the number of CSE patients, but still every year 
reveals new cases (14). Knowledge of the incidence and prevalence of 
CSE is, however, minimal.
CSE frequently leads to disability and early retirement (4,15–17). 
In order to maintain the work ability of solvent-exposed workers and to 
prevent CSE and early retirement, actions should focus on prevention of 
excess exposure, on recognition of symptoms related to solvent-related 
CNS adverse eﬀ ects, and on early detection of CSE. Identifying the 
work tasks and solvent exposure associated with high risk for CSE is 
thus crucial. Diagnosis of CSE relies on evaluation of lifetime exposure, 
clinical examination, and comprehensive diﬀ erential diagnostics by a 
multidisciplinary team. Th e non-speciﬁ city of symptoms, of clinical ﬁ nd-
ings, and of results in diagnostic examinations renders the diagnostics of 
14
1. INTRODUCTION
CSE diﬃ  cult. Furthermore, the veriﬁ cation of persistent, non-progressive 
cognitive dysfunction – the hallmark of CSE – by neuropsychological 
assessments is vulnerable to the interference of multiple confounding 
etiologies (18). It is thus important to evaluate the value of currently 
available diagnostic tools and to develop sensitive and valid diagnostic 
methods which may also elucidate the pathophysiological mechanism 
of CSE.
15
2. REVIEW OF THE LITERATURE
2.1 ORGANIC SOLVENTS
Worldwide, several hundred million tons of organic solvents have been 
widely used annually in household, industry, and other occupational 
settings. Millions of workers are regularly occupationally exposed to 
organic solvents considered neurotoxic (12). 
2.1.1 Classifi cation 
Solvents are substances capable of dissolving or of extracting non-water-
soluble substances (fats, oils, waxes, resins, rubber, asphalt, cellulose 
ﬁ laments, plastic materials) or of remaining in suspension without any 
chemical change in the material or the solvent (13). Compounds from 
many diﬀ erent chemical groups can serve as solvents (Table 1). Th e term 
“organic” refers to compounds that contain carbon bonds and in which 
at least one carbon atom is covalently linked to an atom of another type 
(commonly hydrogen, oxygen, or nitrogen). Organic solvents contain 
at least one carbon and one hydrogen molecule. Aliphatic compounds 
take the form of a chain, whereas aromatic compounds form a 6-carbon 
ring. For a hydrogen group may be substituted some other element such 
as a hydroxyl group in alcohols or a carbonyl group in ketones and es-
ters. Th ey may also contain a substituted halogen element (for example 
chloride) and are thus referred as halogenated hydrocarbons. Here, the 
term “solvent” refers to organic solvents.
Solvents are liquid compounds of low molecular weight, highly 
volatile in the ambient temperature. As a group, they share few physical 
features and even fewer chemical properties, but a common feature is 
lipophilicity and thereby aﬃ  nity for the nervous system.
16
2. REVIEW OF THE LITERATURE
2.1.2 Occupational use 
Solvents may be components in paints, varnishes, lacquers, adhesives, 
glues, and degreasing or cleaning agents, ones used, for example, in the 
production of dyes, polymers, plastics, textiles, printing inks, agricultural 
products, and pharmaceuticals (Table 1) (19). Workers in several occu-
pations and work tasks, such as construction, industrial, metal, and car 
painting, printing-trade workers, ﬂ oor layers and lacquerers, reinforced 
plastic laminators, and wooden surface ﬁ nishers, are typically exposed.
Usually, solvents are used in mixtures to achieve optimal dissolving 
properties. A typical example is White spirit, also called mineral spirit, 
Stoddard solvent, mineral turpentine, petroleum spirit, or mineral 
naphtha, which is a mixture of aliphatic hydrocarbons with a content 
of aromatic hydrocarbons ranging from < 1 to 25%. It is widely used 
in cleaning and degreasing and in paints, lacquers, varnishes, and wood 
preservatives (19). Single-solvent exposure may occur, for example, in 
boat building and lamination (styrene), printing (toluene), and dry-
cleaning (perchloroethylene).
2.1.3 Solvent abuse
Solvents have psychoactive eﬀ ects causing an euphoric state, and thus 
solvent inhalation is a common form of substance abuse (20). Th e most 
commonly used inhalants are spray paints, paint thinners, and glues 
(products containing toluene and xylene), nail polish removers (acetone), 
and gasoline (21). 
Because solvents are widely and easily accessible, legal, and inexpen-
sive, a major problem among children and young adolescents worldwide, 
especially in lower economic groups and among minorities, is solvent 
abuse. It is typically initiated at the age of 8–14, at a younger age than, 
for example, abuse of alcohol or marijuana. Among Australian second-
ary school students, 6% of 12-year-olds but only 1% of 17-year-olds 
reported recent solvent abuse (22). Regular solvent abuse is much less 
common than experimental use: among American secondary school 
students, 1.2% of 13- to17-year-olds reported solvent abuse on 20 or 
more occasions, but even fewer meet criteria for drug dependence (23). 
In Finland, approximately 1–2% of adolescents have had experience 
with solvents (24).
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Chemical 
group
Compound 
(example)
Main occupational use and sources of 
exposure (example)
Aliphatic 
hydrocarbons
n-hexane in glues, paints, lacquers, and printing inks; 
rubber and shoe industries
Aromatic 
hydrocarbons
Toluene in paints, fuel oil, cleaning agents, lacquers, 
paint thinners;
photogravure, printing, car and spray 
painting, linoleum laying
Xylene in paints, lacquers, adhesives, inks, 
varnishes, dyes, glues; 
polyester production, photogravure, spray 
painting, textile and rubber industry
Styrene in solvents, aircraft fuel; boat building
reinforced plastic industry, fiber glass 
production synthesis and manufacture of 
polymers,
copolymers, polyester resins. 
Benzene in fuel, detergents, paint removers; rubber 
production, synthesis of a variety of chemical 
products.
Use prohibited in 1982 except in closed 
systems and in research. If present in solvent 
mixtures, in concentrations of < 0.1 % 
Chlorinated 
hydrocarbons
Trichloroethylene in adhesives, paint removers; degreasing of 
metal components, dry cleaning, textile and 
leather industries 
Perchloroethylene in metal degreasers; dry cleaning, textile 
industry
Trichloroethane in adhesives, inks, glues, paints; cold and dip 
cleaning, degreasing, metal work, printing, 
dry cleaning, leather work
Methylene 
chloride
in metal degreasers, paint and varnish 
removers
Carbon 
tetrachloride
in laboratory, dry cleaning, refrigerant use; 
in Finland restricted to analysis and research 
Alcohols and 
glycols 
Methanol, 
Ethanol, Propanol, 
Butanol,
in solvents and detergents
Ethylene glycol in antifreezes, a polymer precursor
Ketones Methyl ethyl 
ketone
in adhesives, paints, dyes; cleaning, 
coating, paint stripping, in chemical and 
textile industries
Esters Ethyl acetate in paints, in laboratory work
Table 1. Occupationally used organic hydrocarbon solvents with 
neurotoxicity.
18
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Solvent abuse is especially harmful in late childhood and early ado-
lescence, a crucial period for neuromaturation (25). Solvent abuse is 
associated with high rates of co-occurring behavioral and mental-health 
problems and serious medical, neurological, and neuropsychological 
impairments (20,21,25,26).
2.1.4 Pharmacokinetics 
At an individual level, the uptake, distribution, biotransformation, and 
excretion of solvents modify their toxicity. In occupational settings, the 
main route of uptake is generally inhalation of solvent vapors. High 
solvent volatility and large surfaces of evaporation with signiﬁ cant con-
centrations of vapor in the air, lack of appropriate enclosure and exhaust 
ventilation systems, and relatively high temperature of the work environ-
ment all contribute to increased inhalation (27). As alveolar ventilation 
and pulmonary perfusion are functions of physical exertion, physical 
workload is related to increased solvent absorption. Uptake depends 
on the speciﬁ c air-blood partition coeﬃ  cients of each solvent which are 
determined by the alveolo-capillary membrane permeability and the 
solubility of the solvent in blood (28). Substances with low solubility, 
e.g., 1,1,1-trichloroethane, reach saturation levels at relatively low blood 
concentrations and cause less severe CNS disturbances, whereas styrene, 
with its high blood solubility and progressively rising blood concentra-
tions, oﬀ ers increased risk for CNS eﬀ ects (27). 
Part of the inhaled solvent is removed unchanged with expiration. 
Th e rest of the solvent is metabolized in the liver and removed as me-
tabolites in the urine or to a lesser extent in the bile. Solvents and their 
metabolites are distributed to target tissues according to blood supply 
and lipid content of the organ system. Due to their low molecular weight 
and lipophilicity, solvents rapidly cross the blood-brain barrier and may 
accumulate in the brain, especially in myelin (29). 
Th e toxicity and long-term eﬀ ects of solvents depend on the toxicity 
of the solvent itself or its reactive intermediate metabolites. Metabolism 
of solvents occurs in the liver in two phases: Phase I – controlled by the 
cytochrome P450 (CYP) enzyme complex – yields reactive metabo-
lites further detoxiﬁ ed in phase II (30). Many enzymes show genetic 
polymorphisms that may inﬂ uence the neurotoxicity of solvents. Th e 
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phase I isozyme CYP2E1 is relevant to occupational toxicology be-
cause its substrate spectrum includes many solvents such as aliphatic, 
aromatic, and halogenated hydrocarbons. Evidence of the inﬂ uence of 
CYP polymorphisms on the neurotoxicity of solvents is, however, lim-
ited (30–32). Instead, many enzymes of phase II, such as glutathione 
S-transferase M1 (GSTM1) and microsomal epoxide hydrolase (mEH), 
show genetic polymorphisms that aﬀ ect the neurotoxicity of solvents. 
Individuals with the GSTM1 null genotype (GSTM1*0), for example, 
detoxify solvent metabolites more slowly than do those with the positive 
genotype (28,33–35). Th e relative proportion of the GSTM1*0 geno-
type is higher in CSE patients than in solvent-exposed non-CSE cases 
(33,36). Th e same predominance of the GSTM1*0 genotype is evident 
in solvent-exposed workers with psychiatric, neurologic, or cognitive 
symptoms (especially deﬁ cits in sustained attention and short-term 
memory) compared to asymptomatic workers (34). Heavily solvent-
exposed individuals with the GSTM1*0 genotype also appear to be at 
increased risk for Parkinson’s disease (37). GSTM1 thus seems to play a 
protective role against the neurotoxic eﬀ ects of solvents. 
Solvents mainly serve as mixtures, which renders the estimation of 
their pharmacokinetics diﬃ  cult. Interactions between solvents are com-
plicated, and their biological synergistic eﬀ ects have been incompletely 
characterized. Solvents may inhibit or induce each other’s metabolism, 
and their eﬀ ects on each other may be additive, synergistic, or potenti-
ated (28). Enzyme competition and induction may occur also between 
solvents and alcohol or drugs. Alcohol, for example, elevates the for-
mation of styrene-7,8-oxide, a highly toxic metabolite of styrene (29). 
Blood levels of toluene and xylene increase acutely with concomitant 
alcohol ingestion, whereas workers chronically ingesting alcohol have 
lower blood levels of toluene and xylene due to metabolizing enzyme 
induction (38,39). 
2.2 NEUROTOXICITY OF SOLVENTS
A chemical is considered neurotoxic if it is capable of inducing a con-
sistent pattern of structural (i.e. neuroanatomical) change or neural 
dysfunction that causes neurochemical, neurophysiological, or behavioral 
eﬀ ects (40). 
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2.2.1 Neuroanatomical changes
Myelin, with a lipid content of about 70%, is particularly vulnerable to 
the eﬀ ects of lipophilic substances and is thus one of the suggested target 
structures of solvent neurotoxicity. In subjects abusing toluene, a known 
myelinotoxic solvent, neuropathological examinations have revealed 
brain atrophy and gliosis as well as thinning of the corpus callosum and 
damage to myelin with axonal sparing (20,26). Brain magnetic resonance 
imaging (MRI) has revealed diﬀ use brain atrophy, callosal thinning, 
and loss of gray matter – white matter boundaries, hyperintensities in 
the white matter, and hypointensity in the thalami and basal ganglia in 
T2 -weighted images, ﬁ ndings indicating demyelination (26,41–45). 
In magnetic resonance spectroscopy (MRS), lowered N-acetylaspartate 
(NAA), elevated myo-inositol, and unchanged choline levels in the 
centrum semiovale and cerebellum indicate, however, that the principal 
neuropathological mechanism in chronic toluene encephalopathy is 
axonopathy and gliosis, not active demyelination (46). Th e volume of 
cortical gray matter has in MRI also been reduced in frontotemporal 
and parietal areas (47). MRS has, in the thalamus – a neuron-rich gray 
matter structure – shown normal NAA, suggesting, however, absence of 
direct neuronal damage (46). 
Alcohol abuse and the eﬀ ects of ethanol on CNS are widely stud-
ied and may serve as a model to understand the pathophysiological 
mechanisms of other solvents, as well. Neuropathological examination 
of alcoholics reveals reduced brain volume which is mainly attributable 
to a reduction in white matter (48–49, 51–52), MRI of alcoholics has 
shown thinning of the corpus callosum, reduced volume of both white 
and gray matter, and white matter hyperintensities in T2 -weighted im-
ages (50). Even in cases where the macrostructure of the white matter 
appears normal in MRI, magnetic resonance diﬀ usion tensor imaging 
(DTI), which permits quantiﬁ cation of the directionality and coher-
ence of white matter ﬁ ber tracts, shows lowered fractional anisotropy 
(a measure reﬂ ecting the magnitude and orientation of white matter 
tracts) in the centrum semiovale and the genu of the corpus callosum 
(50,56). Th e MRI ﬁ ndings may, however, be reversible and attributable 
not only to the neurotoxic eﬀ ects of alcohol, but also to, for example, 
vitamin deﬁ ciency, electrolyte disturbances, or nutritional and hormonal 
factors (48,51,56).
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Th e only autopsy study on CSE patients revealed no neuropathologi-
cal abnormalities (57), and animal studies have also failed to reveal gross 
histopathological changes related to chronic solvent exposure (58,59). 
Studies on nerve-speciﬁ c marker proteins (e.g., neuron-speciﬁ c enolase, 
creatine kinase-B, beta-S100, glial ﬁ brillary acidic protein) in rats exposed 
to toluene or white spirit indicate, however, activation of astrocytes and 
gliosis in the white matter (59–61). In CSE patients, no abnormalities 
have emerged in the nerve-speciﬁ c marker proteins in cerebrospinal ﬂ uid 
(62). Elevated protein concentrations in the cerebrospinal ﬂ uid of CSE 
patients suggest, however, a protein leak through the damaged blood 
brain barrier (63) and a slight lymphoid reaction indicates non-speciﬁ c 
immunoactivation (64,65).
Brain MRI ﬁ ndings of solvent-exposed workers and CSE patients 
have been normal or have revealed central or cortical atrophy (66–73). 
Some of the MRI studies have also revealed changes similar to those seen 
in association with toluene and alcohol abuse, i.e. reduced corpus cal-
losum volume, loss of gray-white matter discrimination, periventricular 
white matter hyperintensities, and hypointensity in the basal ganglia 
in T2 -weighted images, suggesting solvent eﬀ ects on white matter 
(70,72,74). MRS have on the one hand shown increased choline levels 
in the thalamus, basal ganglia, and parietal white matter in solvent-
exposed workers, indicating demyelination (72). On the other hand, 
a reduced choline, NAA, and N-acetylaspartyl-glutamate level in the 
frontal gray matter in CSE patients indicates abnormalities in neuronal 
viability and axonal density (72). Th e only DTI study on CSE patients 
failed to reveal abnormalities in the white matter tracts (73). All the 
MRI ﬁ ndings are, however, non-speciﬁ c. Even cases with chronic toxic 
encephalopathy due to acute massive solvent intoxication present with 
non-speciﬁ c MRI ﬁ ndings (75,76).
Structural neuroanatomical changes in the CNS related to solvent ex-
posure and also to non-occupational exposure, seem to include neuronal 
loss, axonopathy, and demyelination, although the pathophysiological 
mechanism is unconﬁ rmed. 
2.2.2 Neurochemical changes
Cell cultures and animal studies indicate that solvents induce changes 
in the lipid structure of cell membranes which interfere with synaptic 
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membrane transport mechanisms and disturb intercellular communi-
cation (29,77). Th ey also interact with the lipophilic portions of cell 
proteins which disrupt, for example, fast axonal transport of proteins 
such as neuroﬁ laments (29). Th e neurotoxic mechanisms may diﬀ er 
from one solvent to another, but a common factor is the ability to pro-
mote the synthesis of reactive oxygen species (78,79). Th is may lead to 
free-radical-induced lipid peroxidation, mitochondrial and nucleic acid 
damage, and oxidative stress, all of which play a role in the early phases 
of neuronal apoptosis (78,80,81). 
Th e eﬀ ects of solvents involve complex interactions with neuro-
transmitters and ion channel systems. Th e eﬀ ects of ethanol on neuro-
transmitters have been widely studied in relation to alcohol abuse (82). 
Ethanol-induced inhibition of the release of glutamate – an excitatory 
neurotransmitter in the CNS – and potentiation of the activity of gamma-
aminobutyric acid (GABA) – a major inhibitory neurotransmitter – con-
tribute to the acute depressive eﬀ ects of ethanol on the CNS (83,84). 
Ethanol, as well as some other solvents such as toluene, benzene, xylene, 
and 1,1,1-trichloroethane, acutely inhibits the function of one of the 
glutamate receptors, the N-methyl-D-aspartic acid (NMDA) receptor 
(84,85). Chronic exposure causes adaptive up-regulation in the sensi-
tivity of NMDA receptors, which results in an increased vulnerability 
to glutamate-induced excitotoxicity (77,85,86). NMDA receptors also 
mediate inﬂ ux of Ca2+ ions to the cell, which results, for example, in 
production of reactive oxygen species, release of stored glutamate, and 
increased excitotoxicity (77,85). 
Animal studies have revealed chronic solvent eﬀ ects on monoam-
ine (dopamine (DA), serotonin, and noradrenaline) and cholinergic 
neurotransmitter systems (87). Th e best evidence of solvent eﬀ ects on 
neurotransmitters exists for the dopaminergic system (Fig. 1). Th e high 
vulnerability of the DA system to toxic eﬀ ects results from the functional 
and morphologic properties of DA neurons. Th e axons of DA neurons 
are slow-conducting, small-diameter ﬁ bers with a low conduction safety 
factor and a large projection area (88). Th e fact that DA neurons in the 
hypothalamus and ventral tegmental area are in direct contact with the 
walls of capillary vessels means greater risk for exposure to exogenous 
substances present in blood (88). 
23
2. REVIEW OF THE LITERATURE
Styrene has been shown to induce in solvent-exposed workers an in-
crease in prolactin secretion from the anterior lobe of the pituitary gland, 
suggesting selective vulnerability of DA neurons in the hypothalamus, 
because prolactin secretion is directly controlled by the activity of the 
tuberoinfundibular pathway (TIDA) which runs from the hypothalamus 
to the pituitary gland (Fig. 1) (89–91).
Th at solvents enter the body mainly through the respiratory system 
makes the olfactory mucosa and olfactory receptors particularly vulner-
able to their toxic eﬀ ects. Dopamine-synthesizing periglomerular cells in 
the olfactory bulb are functionally related to the DA system. DA neurons 
from the ventral tegmental area project into limbic forebrain structures 
(nucleus accumbens, olfactory tubercle, amygdala) and cortical areas 
(medial prefrontal cortex, entorhinal cortex) to form the mesocorticol-
imbic DA projection system (Fig. 1) (88). Damage to the rhinencephalic 
(limbic and medial-temporal) structures causes disturbances not only in 
olfaction, but also in cognitive functions such as learning and memory.
Fig. 1. Sagittal section of the brain showing the main dopaminergic path-
ways. Adapted with permission from Australian Prescriber (Fig. 3 in Crocker 
AD. Experimental and clinical pharmacology: Dopamine – mechanisms of 
action. Aust Prescr 1994;17:17–21.)
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Th e DA system is also involved in most visual sensory and percep-
tual functions (88). Lowered visual contrast sensitivity and impaired 
color vision discrimination found in solvent-exposed workers and CSE 
patients (92–97) may be partly due to an interference of solvents with 
the dopaminergic mechanism of retinal cells, although toxic demyelina-
tion of optic nerve or disturbances at higher cortical levels may also be 
involved (94,98,99). 
Solvent exposure also aﬀ ects the nigrostriatal DA projection system. 
Long-term exposure to organic solvents has been shown to increase the 
rate of dopamine synthesis in the brain without aﬀ ecting the number of 
presynaptic terminals or postsynaptic dopamine receptors (100). Th is 
may result from solvent-enhanced catalytic activity of the dopadecarboxy-
lase enzyme or as a response to reduced dopamine D2-receptor aﬃ  nity 
(101). A recent study has shown reduced striatal D2 binding in CSE 
patients and also in asymptomatic solvent-exposed workers, indicating 
more speciﬁ c postsynaptic damage (73).
Exposure to some solvents, such as carbon disulﬁ de, n-hexane, methyl 
alcohol, toluene, methanol, trichloroethylene, and several solvent mix-
tures, has been associated with parkinsonism (88,102–107). Moreover, 
two case-control studies have shown that patients with Parkinson’s disease 
(PD) have been exposed to solvents more frequently than have healthy 
referents (108,109). Occupational exposure to hydrocarbon solvents is 
also a risk factor for earlier onset of PD symptoms and a more severe 
disease course (110,111). Case reports involving positron emission to-
mography (PET) for patients with signs of parkinsonism and long-term 
occupational exposure to hydrocarbons have revealed similar but more 
severe and widespread DA dysfunction and loss of dopaminergic nerve 
terminals than in PD, and also a reduction in dopamine D2 binding sites 
in the caudate nucleus not present in idiopathic PD (102,104).
2.2.3 Neurophysiological changes
Electrophysiological methods provide information on electrical neuronal 
activity. Evoked potentials are electrical responses of the brain generated 
by a sensory (visual, auditory, or somatosensory) stimulus and provide 
information regarding sensory tracts from the site of stimulation to the 
brain cortex. Abnormalities in evoked potentials indicate disturbances 
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in white matter. Results in visual evoked potential (VEP), somatosen-
sory evoked potential (SEP), and brainstem auditory evoked potential 
(BAEP) studies on solvent-exposed workers and CSE patients have been 
inconsistent; they have been normal or have shown prolonged latency 
and both decreased and increased amplitudes (98,112–121). 
In electroencephalography (EEG), synchronous electrical activity 
produced by the ﬁ ring of large neuronal populations in the brain is 
recorded with electrodes attached to the scalp. EEG has excellent time 
resolution, but tissues between the source and the electrodes attenuate 
and distort the EEG signal. EEG may reﬂ ect both local and global cer-
ebral dysfunction with limited exact source localization ability.
EEG is divided into frequency bands reﬂ ecting diﬀ erent degrees 
of brain activity; delta (1–3 Hz), theta (3.5–7.5 Hz), alpha (8.0–11.5 
Hz), beta (12–28 Hz), and gamma (28.5–50.0 Hz). In a healthy, awake 
subject, beta rhythm predominates over anterior, and alpha rhythm over 
posterior brain areas (122). Cortical disorders are related to loss of faster 
frequencies, whereas subcortical disturbances such as vascular dementia 
cause non-speciﬁ c focal or diﬀ use slow-wave abnormalities, i.e., increased 
theta or delta activity (122). Aging is associated with slowing of EEG, 
decreased amplitude of alpha activity, and increased theta and delta power 
(123). In chronic alcoholism, the most frequent ﬁ nding is an increase 
in beta power, but increased theta activity, especially in central and pa-
rietal areas, has also been reported (124,125). EEG studies on solvent-
exposed workers and CSE patients have revealed either normal activity 
or increased beta activity and mainly diﬀ use but in some cases focal slow 
wave abnormalities (15,115,126–131). In addition, quantitatively ana-
lyzed EEG (QEEG) has revealed increased total power and diﬀ erences 
in the anteroposterior distribution, i.e., increased power over anterior 
and decreased power over posterior areas (69,115,116,130,132–134).
EEG reﬂ ects spontaneous electrical activity in the brain, whereas 
event-related potentials (ERP), the so-called “cognitive potentials,” pro-
vide information on electrical responses related to cognitive processing. 
ERPs are generated in tasks where subjects attend to and discriminate 
between stimuli that diﬀ er from one another in some dimension. A clas-
sical paradigm is the “oddball” paradigm in which an infrequent target 
occurs in a background of frequent standard stimuli, and the subject is 
required to respond to the infrequent target stimuli (Fig. 2) (135).
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Fig. 2. Schematic illustration of the oddball paradigm with standard (S) and 
target (T) stimuli presented in a random sequence and the elicited ERP with 
P300 response from the target but not from the non-target (standard) stim-
uli. Reprinted with permission from S. Karger AG, Basel, Copyright © (1999) 
from Frodl-Bauch T et al., Neurochemical substrates and neuroanatomical 
generators of the event-related P300, Neuropsychobiology 1999;40(2), page 
87. 
Th e late components of ERP, such as P300 (a positive waveform with 
peak latency at about 300 ms after the stimulus), represent attention 
allocation, activation of immediate memory, memory updating, and 
decision-making (137). Changes in P300 latency and amplitude occur 
in many conditions aﬀ ecting cognitive processing, such as in depression, 
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PD, and Alzheimer’s disease (138–140). P300 amplitude decreases and 
latency is prolonged also in aging (141). Reduced P300 amplitude is 
associated with several factors, such as drugs, medication, and smoking 
(135,142). In alcoholics, P300 amplitude is decreased, and the decrease 
persists also after long-term abstinence (143). Th e eﬀ ects of alcohol abuse 
on ERP may be related to the neurotoxic eﬀ ects of alcohol. As ERPs 
are, however, genetically determined, the reduced P300 amplitude may 
also reﬂ ect genetic predisposition to alcoholism; the P300 amplitude is 
reduced also in the non-alcoholic relatives of alcoholics (143,144).
In solvent-exposed workers and CSE patients, ﬁ ndings in auditory 
P300 studies have been inconsistent; they have been normal (120) or 
shown either prolonged P300 latency (145,146) or decreased amplitude 
(134). Visual ERP studies have revealed decreased P300 amplitude and 
prolonged latency (114,147).
2.2.4 Solvent effects on cognitive functions 
Th e most consistent cognitive deﬁ cits in occupationally solvent-exposed 
workers and CSE patients are related to attention, performance speed, 
and memory, especially working memory function (148–153). Similar, 
although more severe, disturbances and even dementia may occur in 
association with toluene abuse (26,44,45).
Working memory refers to short-term storage, manipulation, and 
organization of information; it relies on ability to control attention 
(154). Attention can be described as the sustained focus of cognitive 
resources on one aspect of the environment while ignoring or ﬁ ltering 
out other things. Competitive selection is the process that determines 
which information gains access to working memory. Top-down atten-
tion control refers to goal-directed selection of stimuli and response, 
whereas bottom-up saliency ﬁ lters automatically enhance the response 
to infrequent and unexpected stimuli (Fig. 3) (155).
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Fig. 3. Functional components of attention. Information about the world 
is processed by salience filters that respond differentially to infrequent or 
important stimuli (bottom-up). A competitive process selects the represen-
tation for entry into the circuitry that underlies working memory. Working 
memory can direct top-down bias signals that modulate the sensitivity of 
representations that are being processed in working memory. The selection 
process can also direct top-down bias signals that reflect the result of the 
competitive selection. Working memory and competitive selection direct 
eye movements and other orienting behaviors. Voluntary attention involves 
working memory, top-down sensitivity control, and competitive selection 
operating as a recurrent loop (dark arrows) (155). Reprinted from Annual 
Review of Neuroscience 2007(30), page 59, with permission from Annual 
Reviews, Copyright © 2007. 
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Functional neuroimaging has shown that tasks requiring working 
memory activate the prefrontal, parietal, and anterior cingulated cortex as 
well as parts of the basal ganglia (Fig. 4) (156,157). Striatal dopaminergic 
function mediates working memory capacity and, for example, load-
dependent prefrontal cortex activation, which also leads to changes in 
the activity of parietal regions (158–160). Dorsolateral prefrontal cortex 
is involved in organization, manipulation, and encoding of information 
and is activated together with the dorsal parietal cortex in top-down 
attention control (Fig. 4) (161,162). Dorsolateral prefrontal cortex is 
suggested to act as a trigger for the dorsal parietal cortex to, for example, 
disengage and shift attention to a previously unattended stimulus. Select-
ing, comparing, and deciding on information held in memory activates 
the ventrolateral prefrontal cortex, which is involved together with the 
ventral parietal cortex in bottom-up attention control (Fig. 4) (162,163). 
Th e dorsal part of the anterior cingulate cortex, which is connected to the 
prefrontal and parietal cortex, motor brain areas, and frontal eye ﬁ elds, 
is a central station for processing top-down and bottom-up stimuli and 
is involved in attentional processes to initiate action and suppress inap-
propriate responses (163).
In solvent-exposed workers with cognitive impairment, PET during 
a working memory task has revealed activation of the frontal cortex in 
atypical areas, suggesting neural compensation (164). Functional com-
pensation in frontal areas has also been evident in aging, which is, as is 
CSE, accompanied by slowed information processing speed and a decline 
in working memory and attentional abilities (157,165,166).
Th e neuropsychological deﬁ cits in CSE resemble qualitatively those 
of Parkinson’s disease (148,167). In Parkinson’s disease, they have been 
linked to nigrostriatal dopamine depletion which disrupts the normal 
pattern of basal ganglia outﬂ ow and aﬀ ects normal transmission of 
information through the frontostriatothalamic circuitry (168,169).
Th is circuitry, which connects the frontal lobes to the basal ganglia 
and mediates cognitive, behavioral, and motor functions, accounts for 
psychomotor speed (168). Impaired psychomotor speed has in CSE 
patients and asymptomatic solvent-exposed workers been shown to as-
sociate with reduced striatal D2 binding (73), a reduction associated also 
with impairment in neuropsychological tests requiring abstraction and 
mental ﬂ exibility, attention, and response inhibition, i.e., frontal brain 
functions; it has been shown to be associated also with aging (170,171). 
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In alcoholics, their cognitive deﬁ cits (deﬁ cits in abstract problem-
solving, visuo-spatial and verbal learning, perceptual motor skills, speed 
of information processing, attention, and working memory) may also be 
related to disruption of DA connectivity within the prefrontal region and 
between frontal and parietal regions. A reduced number of cholinergic 
neurons in the basal forebrain and changes in cholinergic neurotrans-
mission, however, also account for the cognitive disturbances seen in 
alcoholism (56,86,172–174). 
Fig. 4. Brain areas involved in working memory and attention. Copied under 
license from the Canadian Medical Association and Access Copyright © 
2009, from aan het Rot et al., Neurobiological mechanisms in major depres-
sive disorder, Canadian Medical Association Journal 2009;180(3);page 310. 
Further reproduction prohibited.
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Cognitive deﬁ cits related to CSE seem to share similarities with 
alcoholism, Parkinson’s disease, and aging, and suggest fronto-temporo-
parietal dysfunction related to disturbances in frontostriatothalamic 
circuitry. Th e cognitive performance of CSE patients corresponds to 
that of 20-year-older healthy subjects (175,176). It has thus been hy-
pothesized that in CSE the neurotoxic solvent eﬀ ects lead to premature 
aging (58,175), a hypothesis suggested also in association with alcohol-
ism (177).
2.3 OCCUPATIONAL CHRONIC SOLVENT 
ENCEPHALOPATHY 
Acute solvent exposure typically causes symptoms such as dizziness, 
disorientation, euphoria, and a feeling of drunkenness – symptoms 
somewhat resembling those seen with excessive alcohol use. Increasing 
levels of solvent exposure may lead to confusion progressing to uncon-
sciousness, convulsions, and death. Th e acute, transient eﬀ ects of solvents 
result from their pharmacological actions and subsequent neurochemical 
changes in the CNS, which does not necessarily indicate neurotoxicity 
(40). Acute massive exposure (178) and long-lasting low-level solvent 
exposure (15,179) has, however, proven neurotoxic and may lead to 
non-reversible chronic encephalopathy. 
2.3.1 Epidemiology
Worldwide, knowledge as to the prevalence and incidence of CSE is 
limited. In New Zealand, with a population of about 4.2 million, 76 
CSE cases were diagnosed between 1993 and 1997 (3.6 cases per million 
inhabitants annually) (8). A more recent survey from the Netherlands, 
with a population of 16 million, reported 396 CSE cases between 1997 
and 2006 (2.5 cases per million inhabitants annually) (180). In 1997, a 
European survey estimated the incidence of CSE which varied from 0.1 
to 16.8 cases per million employed (2). Th is huge variety in incidence is 
partly due to national diﬀ erences in the diagnostic procedure, criteria, 
and acceptance of CSE as an occupational disease. Studies on the inci-
dence of CSE in populations at risk, i.e., those occupationally exposed 
to organic solvents, are lacking. 
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2.3.2 Diagnostic criteria 
In 1985, a working group of the World Health Organization (WHO) 
presented diagnostic criteria and a classiﬁ cation for solvent-induced 
chronic toxic encephalopathy (Table 2) (181). Two years later, the 
“Workshop on neurobehavioral eﬀ ects of solvents” in Raleigh, North 
Carolina, USA, introduced a somewhat diﬀ erent classiﬁ cation which 
divides patients of WHO class II into those with sustained personality 
or mood change (type 2A) and those also with impairment of cognitive 
functions (type 2B) (182). 
Table 2. Classiﬁ cation of chronic solvent encephalopathy according to 
WHO
Symptoms Cognitive 
deficits
Neurological 
deficits
Class I
Organic affective 
syndrome
Fatigue, difficulties in 
memory and concentra-
tion, loss of initiative.
Change in personality, 
poor impulse control, 
lowered mood and moti-
vation, irritability, anxiety, 
emotional lability
No objective 
dysfunction
No
Class II
Mild chronic toxic 
encephalopathy
Difficulties in concen-
tration and attention, 
impairment of memory, 
decrease in learning 
capacity
Objective 
evidence of 
cognitive 
impairment
Minor 
neurological 
signs
Class III
Severe chronic 
toxic 
encephalopathy
Marked global 
deterioration in intellect 
and memory
Marked global 
deterioration 
in intellect and 
memory
Neurological 
signs or 
neuroradiological 
findings
Th e International Classifi cation of Diseases, tenth edition (ICD-10), 
classiﬁ es CSE as a toxic encephalopathy (G92) with a deﬁ ned causal agent 
(*T52.x; organic solvents) (183). Th e Diagnostic and Statistical Manual for 
Mental Disorders, fourth edition (DSM-IV), lacks any speciﬁ c code for 
CSE, but it can be classiﬁ ed as a substance-induced persistent dementia 
(292.82), amnestic (292.83), or other cognitive disorder (294.9) (184).
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Worldwide, the diagnostic criteria and classiﬁ cation of CSE are used 
inconsistently. In 1998, only 8 of 18 centers in European countries, 
the United States, and New Zealand used the WHO or Raleigh clas-
siﬁ cation. Th e other centers used ICD-10, DSM-IV, or some national 
classiﬁ cation (6). 
Th e diagnosis of CSE relies on (1) veriﬁ cation of substantial long-
term exposure to organic neurotoxic solvents, (2) a characteristic clini-
cal picture of organic nervous system damage with typical subjective 
symptoms and objective ﬁ ndings in clinical and auxiliary examinations, 
(3) exclusion of other organic brain disorders and primary psychiatric 
diseases (7,181,182,185). In 1994, an expert group convened by the 
European Commission suggested requesting a minimum duration of 
exposure of 10 years (186). Less may be accepted in cases with particularly 
high concentrations. Later, the latency between cessation of exposure 
and symptoms has been restricted to no more than a few months (187). 
2.3.3 Diagnostic procedure 
Th e initial step in CSE diagnostics is the recognition of symptoms as 
solvent-related adverse eﬀ ects. Euroquest – a neurotoxic symptom ques-
tionnaire – has proven feasible in the early recognition of neurotoxic 
symptoms, for example, in primarily health care or occupational health 
services (OHS) (188,189). In Finland, cases with a suspicion of CNS 
adverse eﬀ ects related to occupational solvent-exposure are, after primary 
diﬀ erential diagnostics (exclusion of depression, sleep disturbances, and 
alcohol abuse as the primary cause), referred to the Finnish Institute of 
Occupational Health (FIOH) in Helsinki, where the diagnostic proce-
dure has been centralized since the 1990s (185).
Th e diagnostic procedure at the FIOH includes evaluation of all 
previous medical records and available documents relating to exposure, 
interviews and clinical examinations by specialists in occupational 
medicine and neurology, brain imaging with MRI, diﬀ erential diagnostic 
laboratory testing, and at least one, usually several, comprehensive clini-
cal neuropsychological assessments. If other possible causes of cognitive 
dysfunction – most often psychiatric or sleep disorders – are suspected, 
further studies are carried out. Other examinations, such as EEG, 
evoked potentials, ERP, ophthalmic and visual function examinations, 
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and analyses of cerebrospinal ﬂ uid have been useful, but their diagnostic 
value has remained undetermined. Th e diagnosis of CSE is made after a 
follow-up of at least one year to exclude reversible or progressive symp-
tomatology. During follow-up, occupational solvent exposure is halted 
or is minimized, and other possible medical disorders are treated. Finally, 
clinical and neuropsychological re-evaluations are carried out, and the 
CSE diagnosis is veriﬁ ed by a multidisciplinary team (14,185).
Th e survey of van der Hoek et al (6) revealed that in 1998 in most 
of the European countries, the United States, and New Zealand, an 
occupational physician and a neuropsychologist usually examine the 
patients, and neurologists, psychiatrists, and occupational hygienists 
are consulted when necessary. Blood tests, EEG, brain imaging, elec-
troneuromyography, and evoked or event-related potentials were used 
on indication only (6). Th e expert group convened by the European 
Commission stated in 2009 that the diagnosis should be established 
as a result of examinations by a specialist in occupational medicine, a 
neurologist, and a neuropsychologist in conjunction (187).
2.3.4 Assessment of exposure 
Assessment of occupational solvent exposure is essential in the diagnostics 
of CSE but is diﬃ  cult to qualify and quantify. Worldwide, assessment 
of exposure in clinical settings is variable. Some centers use interviews, 
measurements at the workplace, biological monitoring, industrial hy-
gienic data and job-exposure matrix, or exposure indices calculated in 
several ways (6). 
Classiﬁ cation of lifetime exposure solely by duration of occupational 
solvent exposure in years may result in misclassiﬁ cation of subjects, 
because the level of solvent exposure, content of solvent mixtures, and 
working conditions change over time (190). Retrospective assessment 
of life-time solvent exposure based on recall is also prone to errors and 
over- or underestimation of exposure (191,192). Biological markers, for 
example urinary hippuric acid levels for toluene and mandelic acid levels 
for styrene, can serve in the assessment of exposure to single solvents. 
Current biological monitoring and hygienic measurements at the work-
place are useful for surveillance of exposed workers but are unsuitable 
for assessment of past exposure. Th e most valid assessment procedures 
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are job-speciﬁ c questionnaires and detailed interviews combined with 
an evaluation by an expert (192,193). 
Exposure indices, which can be calculated in several ways, provide an 
estimate of cumulative dose and intensity of lifetime exposure (194,195). 
Occupational Exposure Limit Years (OELY) has been used at FIOH. One 
OELY is equivalent to working eight hours a day for one year with solvent 
exposure at the level of the Finnish Occupational Exposure Limit (OEL) 
of 1981, which correspond to the concurrent threshold limit values of 
the American Conference of Governmental Industrial Hygienists (196). 
In clinical practice at FIOH, six or more OELY is considered requisite 
for the diagnosis of CSE, assuming that all the other diagnostic criteria 
are met (14).
2.3.5 Symptoms and clinical signs
CSE patients present with a wide variety of non-speciﬁ c neurological, 
mood-related, and cognitive symptoms. Th e most prevalent symptoms 
include headache, dizziness and imbalance, sleeping problems, fatigue, 
irritability, emotional lability, decreased initiative, and depressed mood 
(see Table 2). Th e hallmark of CSE is the cognitive symptoms: impaired 
memory and diﬃ  culties in concentration (14,16,189,197,198). Th is 
symptom domain in Euroquest also has the best power in discriminat-
ing between workers with CSE and unexposed referents (188,189). 
Th e symptoms of CSE are non-progressive and are usually alleviated 
slightly after cessation of exposure, although diﬃ  culties in memory and 
concentration tend to remain (189,199). 
Th e clinical neurological examination is usually normal or may reveal 
slight non-speciﬁ c abnormalities such as disequilibrium, impaired ﬁ ne 
motor control, and dyscoordination (15,126,197,198). 
2.3.6 Diagnostic methods
Brain imaging
Brain computerized tomography (CT) of CSE patients may be normal 
or reveal slight brain atrophy (66,197,200,201). MRI, which is more 
sensitive in assessing brain atrophy and white matter changes (66), may 
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also be normal or reveal central and cortical atrophy (66,70,73). One 
MRI study on CSE patients has also revealed loss of gray-white mat-
ter discrimination, periventricular white matter hyperintensities, and 
hypointensity in the basal ganglia in T2 -weighted images, indicating 
solvent eﬀ ects in the white matter (70).
Single photon emission computed tomography (SPECT), which 
measures blood ﬂ ow in the brain and indirectly brain metabolism, has 
in CSE patients revealed decreased blood ﬂ ow mainly in temporal, fron-
tal, and parietal areas (127,202,203). PET with ﬂ uorodeoxyglucose, a 
direct measure of glucose metabolism, has in two CSE case reports, one 
with long-term solvent exposure and one with acute tetrabromoethane 
intoxication, revealed fronto-parietal and subcortical (basal ganglia, 
amygdala, hippocampus) hypometabolism (204,205). 
Neurophysiological methods
EEG in CSE patients may be normal or reveal increased beta activity 
and mainly diﬀ use but in some cases local slow wave abnormalities 
(increased theta and delta power) (15,126–128,131). Due to large 
individual variation in EEG and subjective visual interpretation of the 
recordings, this method is less sensitive in revealing slight brain involve-
ment. QEEG provides a more sensitive and objective method to analyze 
electrical activity of the brain. In CSE patients it has revealed increased 
beta or total power and diﬀ erences in the anteroposterior distribution 
of electrical activity (132,134).
Decreased amplitude may be visible in VEP (114),(98,112–118) 
and auditory or visual ERP may reveal prolonged latency or decreased 
amplitude of the P300 component (114,134,145,146). Th e only ERP 
study with a dual task paradigm has also shown decreased ERP ampli-
tudes (134). 
Neuropsychological assessment 
In the clinical neuropsychological assessment, CSE patients show mild 
to moderate deﬁ cits in memory and learning, attention and allocation 
of attentional resources, visuospatial functions, abstract reasoning, and 
speed of information processing (148,149,151–153) 
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In order to standardize clinical assessments and diagnosing of CSE, 
the WHO advised in 1986 a standardized core battery of neuropsycho-
logical tests focusing on psychomotor functioning, memory, and atten-
tion (181). Th e survey of van der Hoek et al revealed, however, that in 
1998 in most of the European countries, the United States, and New 
Zealand, the neuropsychological test batteries used in clinical practice 
were heterogeneous (6). Th e expert group convened by the European 
Commission suggested in 2009 that the neuropsychological test battery 
should include tests of verbal and visual memory, attention, psychomotor 
speed, and abstraction ability. Primary intellectual ability, previous intel-
lectual level, and education should be evaluated, as well as cooperation 
and eﬀ ort during the tests (187). 
Auxiliary methods
Ophthalmic and visual function examinations of CSE patients may 
reveal lowered visual contrast sensitivity and impaired color vision 
discrimination (92–94). Audiological and otoneurological tests may 
reveal hearing loss and disturbances in the vestibulocerebellar system 
(206–209). Hyposmia may also be discovered (210). Laboratory tests 
are usually normal and serve mainly as diﬀ erential diagnostic tools 
(211). Cerebrospinal ﬂ uid examination is also usually normal, but may 
reveal non-speciﬁ c abnormalities such as a slight lymphoid reaction or 
an increase in protein concentration (62–64).
Case report
A 48-year-old man, who had been working as a spraypainter and a sand-
blaster for 28 years, was diagnosed with CSE in 1995. He had no other 
diseases and used no medication. He had been smoking for 33 years, and 
his reported alcohol consumption was on average 4 to 5 doses per week. 
He had been exposed mainly to White spirit, xylene, and butanol, and 
the exposure had been heavy (OELY 16). Th is solvent-exposure work 
halted in 1994. 
Th e clinical neurological examination was normal. Th e neuropsycho-
logical assessment revealed impaired psychomotor speed, slight dyspraxia, 
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diﬃ  culties in allocation of attention, impairment of verbal memory, and 
interference with memory functions. 
Th e brain MRI in 1994 revealed slight non-speciﬁ c changes in deep 
white matter (Fig. 5). In the CSF analysis, the proportion (72%) of cells 
in the monocyte-macrophage line was increased, indicating chronic CNS 
irritation. EEG and ERP were recorded in 1994 and in 1995. Th e visual 
EEG readings were normal. Th e quantitative analysis of the EEG in 1994 
revealed increased delta activity throughout the brain, especially over 
the frontocentral area, and a slight increase emerged over the convexity 
in the theta activity. Th e P300 latency of auditory ERP was prolonged 
in both of the recordings (380.7 ms and 385.5 ms), and in the second 
recording, the P300 amplitude was decreased (5.8 μV and 4.4 μV) (Fig. 
5). VEP in 1995 was normal. Ophthalmic and visual function examina-
tions revealed slight congenital protanopia; otherwise no abnormalities 
appeared in color vision, contrast sensitivity, or visual ﬁ elds. It was stated 
that the patient was unable to any work, and he was granted a disability 
pension. During the follow-up of six years, the patient’s condition, symp-
toms, and ﬁ ndings in neurological and neuropsychological examinations 
remained stable. He was also diagnosed with occupational asthma and 
occupational perceptive hypoacusis.
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Fig. 5. (A) The brain MRI of a 48-year-old spraypainter-sandblaster diagnosed 
with CSE in 1994 revealed small focal hyperintensities in deep white matter in 
T2 -weighted images. (B) The auditory ERP in 1994 revealed prolonged P300 
latency (380.7 ms) but normal amplitude (5.8 μV). (C) In 1995, the P300 latency 
was prolonged (385.5 ms) and amplitude decreased (4.4 μV). The lower response 
curve is filtered with 6 Hz lowpass.
(A)
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2.3.7 Differential diagnoses
In the diﬀ erential diagnostics of CSE, CNS disorders such as cerebrov-
ascular diseases, neurodegenerative disorders (Alzheimer’s disease, Par-
kinson’s disease), infections and inﬂ ammatory brain diseases (multiple 
sclerosis), neoplasms and paraneoplastic syndromes, and traumatic brain 
disorders must be excluded. Other conditions which share similarities 
with the symptoms and cognitive dysfunction in CSE include metabolic 
causes (avitaminosis, thyroid disorders), depression, sleep disorders, and 
alcohol- or substance abuse (187).
Major depression shares many symptoms with CSE such as fatigue, 
loss of initiative, memory impairment, diﬃ  culty in concentration, and 
irritability (184) and is thereby a diﬀ erential diagnostic challenge. Th e 
most typical axis I mood disorders in CSE patients and solvent-exposed 
workers are depression and anxiety (212,213). It is, however, diﬃ  cult 
to determine whether the psychiatric symptoms in CSE have an organic 
etiology or are psychological reactions secondary to a decrease in func-
tionality and quality of life (214,215). 
Psychiatric and mood symptoms may also contribute to poor per-
formance in neuropsychological tests (216). Many other potentially 
confounding and eﬀ ect-modifying factors, such as pre-exposure intel-
lectual capacity, developmental learning diﬃ  culties, education, alert-
ness in the test situation, pain, alcohol use, and medication, inﬂ uence 
neurobehavioral test performance and make the interpretation diﬃ  cult 
(18,217). Furthermore, patients with suspected CSE may be involved 
in litigation or ﬁ nancial compensation procedures depending on the 
national compensation system and may show insuﬃ  cient eﬀ ort and 
suboptimal performance in test situations (153,218).
CSE patients frequently report sleeping problems, such as diminished 
sleep quality, diﬃ  culties falling asleep, frequent awakenings and trouble 
falling asleep again, waking up too early, and feeling tired upon awaken-
ing (189). Th ese symptoms may be related to, for example, mood disor-
ders but also to solvent exposure itself (219). Symptoms of sleep apnea 
syndrome, such as fatigue, forgetfulness, and concentration problems, 
are also very similar to those reported by CSE patients, and it has been 
argued that solvent-exposed workers with sleep apnea could have been 
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misdiagnosed as CSE cases (219,220). Solvent exposure may, however, 
induce or at least aggravate sleep apnea (219–222). 
Chronic alcohol abuse frequently associates with disturbances in 
working memory, learning, visuospatial abilities, executive functions, and 
psychomotor speed (174,223) which may be diﬃ  cult to distinguish from 
the ones caused by long-term occupational solvent exposure. Excessive 
alcohol consumption and risk for alcoholism is increased among solvent-
exposed workers and thus must be considered in diﬀ erential diagnostics 
(224–226). Ataxia and polyneuropathy often associated with alcohol 
abuse are, however, typically absent in CSE (15,185,197,227).
Other concurrent etiologies do not, however, prohibit the diagnosis 
of CSE as an occupational disease. In Finland, the diagnosis can be 
made if occupational etiology is considered to account for at least 50% 
of the etiology.
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Th e aims were distributed among the ﬁ ve studies as follows:
Study I deﬁ ned the number and incidence of CSE cases in Finland during 
1995–2007, evaluated the duration and nature of exposure, identiﬁ ed 
the work tasks where CSE was encountered, and elucidated the conse-
quences of CSE for the patient’s work ability and reasons for rejection 
of CSE diagnosis in suspected cases.
Study II characterized the brain MRI ﬁ ndings in CSE patients and 
evaluated the diagnostic value of brain MRI in CSE.
Study III characterized the QEEG ﬁ ndings in CSE patients and evalu-
ated the diagnostic value of QEEG in CSE.
Study IV characterized the P300 component of auditory ERP in CSE. 
It also evaluated the implication of the results for the diagnostics of CSE 
and for the understanding of the pathophysiology of CSE.
Study V aimed to develop a more sensitive ERP method for the diagnos-
tics of CSE and to improve the understanding of the brain dysfunction 
and pathophysiology of CSE.
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4.1 Patients and controls
Th e diagnosis of occupational CSE of all the patients included in the 
ﬁ ve studies had been done according to the routine clinical diagnostic 
procedure at FIOH. All patients fulﬁ lled the criteria for non-reversible 
and non-progressive toxic encephalopathy due to occupational solvent 
exposure type 2B according to the classiﬁ cation by the International 
Solvent Workshop or class II of the WHO criteria (181,182). Brain 
MRI (Study II), EEG (Study III), and ERP (Study IV) had been part 
of the clinical diagnostic procedure. Clinical and exposure information 
was collected from the patient records of FIOH. 
Study I: incidence, solvent exposure, and work tasks of CSE 
patients
Th e material consisted of all patient records of CSE cases diagnosed 
at FIOH during 1995–2007. Records of the patients referred during 
2002–2004 were analyzed in detail to reveal CSE patients’ ability to work. 
We also included all the workers referred to FIOH during 1995–2005 
due to a suspicion of CSE to study the proportion of those diagnosed 
among all referred cases. Of the cases referred during 2002–2004, we 
also analyzed the main reasons for rejection of a CSE diagnosis. 
Study II: magnetic resonance imaging of the brain
In order to characterize the brain MRI ﬁ ndings in CSE, clinical informa-
tion on 153 patients diagnosed at FIOH between 1991 and 2003 with 
occupational chronic toxic encephalopathy was collected from patient 
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records. Exclusion criteria were toxic encephalopathy due to other than 
solvent exposure, such as lead or aluminium encephalopathy, brain 
imaging only with CT, any other concomitant brain disorder, previous 
traumatic brain injury, and alcohol consumption exceeding on average 
1200 g absolute alcohol per month (40 g or 3–4 units of absolute alcohol 
per day) for men and 820 g for women during the preceding year. Two 
patients with encephalopathy due to acute solvent intoxication were 
excluded. MRI data on 25 patients was unavailable for re-analysis of the 
images. Th e ﬁ nal number was 71. Patient characteristics are in Table 4.
Study III: quantitative electroencephalography
During 1994–2000, an EEG recording had been done for 59 CSE 
patients without any other brain disorder, previous traumatic brain in-
jury, or psychiatric disease apart from depression. Exclusion criteria for 
reported alcohol consumption were applied as in Study II. Because of 
gender diﬀ erences in EEG, females (n=7) were excluded from the study, 
as were four patients on benzodiazepine and one on carbamazepine 
medication. Th e ﬁ nal number of patients was 47. Eight of them were 
on a medication with an inﬂ uence on the central nervous system (CNS 
medication), such as tricyclic antidepressants or selective serotonin re-
uptake inhibitors. 
We used two control groups. Th e male blue-collar workers of the 
age-matched control group had participated during 1991–1995 in a 
large study at FIOH investigating the predictors of work capacity and 
disability pension in aging construction workers (228). In that study, 200 
subjects had been randomly selected from the original sample of 1000 
subjects for further medical, neurophysiological, and neuropsychological 
evaluation. From this data set, we excluded 77 subjects (39%) due to a 
job-title indicating possible occupational solvent exposure. A further 23 
subjects were excluded by the same exclusion criteria as for CSE patients. 
Th e ﬁ nal number of age-matched controls was 100. For the laboratory’s 
reference EEG values, healthy subjects had been recruited mainly from 
the staﬀ  of FIOH, and the 24 male subjects formed the laboratory con-
trol group. Characteristics of patients and the controls are in Table 4.
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Study IV: auditory event-related potentials
Auditory ERP recording had been done for 104 (83%) of the 125 patients 
diagnosed with CSE at FIOH during 1993–2002. Patients excluded due 
to some other brain disorder, previous traumatic brain injury, psychiatric 
disease apart from depression, or excessive alcohol consumption (criteria 
applied as in Study II) numbered 34. We also excluded two patients with 
encephalopathy due to acute solvent intoxication and three patients with 
unidentiﬁ able ERP waves. Th e ﬁ nal number of patients was 86, with 
eight female. Ten patients were on CNS medication: antidepressants, 
anxiolytics, or analgesic drugs. A second ERP recording, done an aver-
age 14 months (range, 10–18) after the ﬁ rst one, involved 19 patients.
We used two control groups. Th e age- and education-matched con-
trol group was selected from the same worker population as in Study 
III by the same exclusion criteria. As the ERP waves of two control 
subjects were unidentiﬁ able, the ﬁ nal number of matched controls was 
108 with eight being female. None of the matched controls was on 
CNS medication. Th e laboratory’s own reference ERP values on the 84 
healthy subjects, recruited mainly from the staﬀ  of FIOH, formed the 
laboratory control group. 
In order to compare ERP results to cognitive parameters, we chose 
three subtests from the Wechsler Adult Intelligence Scale (WAIS) or 
WAIS-revised that measure various aspects of attention and short-term 
memory functioning: Digits Forward, Digits Backward, and Digit 
Symbol Substitution (229,230). Th ese tests had been part of the com-
prehensive clinical neuropsychological assessment during the clinical 
diagnostic procedure of all CSE patients in the auditory ERP study. Th e 
same tests were also part of the neuropsychological test battery of the 
matched controls (228).
CSE patients’ performance was inferior to that of the matched con-
trols on all three neuropsychological tests (Table 3). Characteristics of 
patients and controls are in Table 4.
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Table 3. Performance of patients with chronic solvent 
encephalopathy and age- and education-matched controls in 
neuropsychological tests
Patients (n=86) Controls (n=108)
mean SD range mean SD range p-value
Digits Forward 5.4 1.0 3–8 6.0 1.1 3–9 <0.001
Digits Backward 4.0 1.0 2–7 4.5 1.2 2–8 <0.001
Digit Symbol Substitution 30.3 8.8 16–60 35.5 10.2 13–67 <0.001
Study V: multimodal event-related potentials 
All 16 patients diagnosed with CSE at FIOH during 2004–2007 were 
asked to participate in the study. In order to perform a follow-up study 
on the cognitive performance of CSE patients, 10 patients diagnosed 
during 2001–2003 – ones who had participated in a study (unpublished) 
at FIOH in 2004–2005 characterizing the memory performance proﬁ le 
of CSE patients – were also contacted. Refusals and non-reachable cases 
numbered 11. One case was excluded from the study group due to tech-
nical failure in ERP registration and three cases due to depression. Th e 
ﬁ nal number of patients was 11, one female. Th e mean time from the 
CSE diagnosis to the study was 3.7 years (SD 2.0, range 1–8). 
Th e age-matched control group comprised 13 subjects without any 
history of solvent exposure or neurological diseases. All the patients and 
controls completed a questionnaire inquiring about their education, 
health, medication, and alcohol consumption. None of the patients or 
controls had previous traumatic brain injury, depression or any other 
psychiatric disease, or excessive alcohol consumption (criteria applied 
as in Study II).
Characteristics of patients and the controls are in Table 4.
47
4. MATERIALS AND METHODS
Ta
b
le
 4
. C
h
ar
ac
te
ri
st
ic
s 
o
f 
ch
ro
n
ic
 s
o
lv
en
t 
en
ce
p
h
al
o
p
at
h
y 
p
at
ie
n
ts
 a
n
d
 t
h
ei
r 
co
n
tr
o
ls
 in
 S
tu
d
ie
s 
II–
V.
St
u
d
y 
IIa
St
u
d
y 
III
b
St
u
d
y 
IV
c
St
u
d
y 
V
d
 
Pa
ti
en
ts
 
n
=
71
Pa
ti
en
ts
 
n
=
47
C
o
n
tr
o
ls
 
n
=
10
0
La
b
o
ra
to
ry
-
co
n
tr
o
ls
  
n
=
24
Pa
ti
en
ts
 
n
=
86
C
o
n
tr
o
ls
 
n
=
10
8
La
b
o
ra
to
ry
-
co
n
tr
o
ls
 
n
=
84
Pa
ti
en
ts
 
n
=
11
C
o
n
tr
o
ls
 
n
=
13
A
ge
 (y
ea
rs
)
 
 
 
 
 
 
 
 
   
M
ea
n 
(S
D
)
51
.0
 (7
.2
)
50
.6
 (5
.8
)
50
.1
 (6
.8
)
39
.8
 (9
.0
)
50
.1
 (6
.3
)
49
.8
 (6
.8
)
41
.1
 (1
0.
2)
59
.5
 (3
.8
) 
59
.4
 (4
.5
) 
   
ra
ng
e
33
–7
3
33
–6
1
40
–6
5
25
–6
5
34
–6
1
40
–6
5
20
–6
3
53
–6
6 
52
–6
6 
D
EY
e
 
 
 
 
 
 
 
 
   
M
ea
n 
(S
D
)
27
.1
 (8
.1
)
27
.5
 (8
.1
)
0
0
27
 (7
.5
)
0
0
33
.5
 (8
.1
) 
 
   
ra
ng
e
11
–4
9
11
–4
3
11
–4
3
 
 
17
–4
2 
 
O
EL
Y
f
 
 
 
 
 
 
 
 
 
   
M
ea
n 
(S
D
)
10
.8
 (4
.4
)
10
.7
 (4
.2
)
0
0
10
.8
 (4
.4
)
0
0
11
.0
 (3
.8
) 
 
   
ra
ng
e
6–
23
5–
21
 
 
6–
26
 
 
7–
17
 
 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(g
/m
on
th
)g
 
 
 
 
 
 
 
 
 
   
M
ea
n 
(S
D
)
17
3 
(2
26
)
20
5 
(2
59
)
38
1 
(3
41
)
N
A
15
8 
(1
99
)
36
4 
(3
38
)
N
A
14
0 
(1
54
) 
13
7 
(1
62
) 
   
ra
ng
e
0–
96
0
0–
10
80
0–
11
54
N
A
0–
76
8
0–
11
54
 
0–
48
0 
  0
–4
80
  
Sm
ok
er
s 
(%
)
37
30
N
A
N
A
34
43
N
A
27
 
0
H
yp
er
te
ns
io
n 
(%
)
13
13
N
A
N
A
17
13
N
A
27
 
15
D
ia
be
te
s 
(%
)
6
6
N
A
N
A
6
0
N
A
0 
0
Ed
uc
at
io
n 
(y
ea
rs
)
 
 
 
 
 
 
 
 
 
   
M
ea
n 
(S
D
)
N
A
N
A
N
A
N
A
7.
2 
(1
.4
)
7.
1 
(1
.9
)
N
A
9.
1 
(1
.2
) 
12
.2
 (3
.5
) 
   
ra
ng
e
 
 
 
 
6–
12
4–
15
 
7–
11
 
6–
19
 
a 
 M
ag
ne
tic
 r
es
on
an
ce
 im
ag
in
g 
st
ud
y 
w
ith
ou
t 
co
nt
ro
ls
 
b 
 E
le
ct
ro
en
ce
ph
al
og
ra
ph
y 
st
ud
y
c 
 A
ud
ito
ry
 e
ve
nt
-r
el
at
ed
 p
ot
en
tia
ls
 s
tu
dy
d 
 M
ul
tim
od
al
 e
ve
nt
-r
el
at
ed
 p
ot
en
tia
ls
 s
tu
dy
e 
 D
ur
at
io
n 
of
 o
cc
up
at
io
na
l e
xp
os
ur
e 
in
 y
ea
rs
f 
 O
cc
up
at
io
na
l e
xp
os
ur
e 
lim
it,
 y
ea
rs
g  
A
lc
oh
ol
 c
on
su
m
pt
io
n 
du
rin
g 
th
e 
pr
ec
ed
in
g 
ye
ar
  w
as
 a
sk
ed
 in
 a
 q
ue
st
io
nn
ai
re
, p
at
ie
nt
s 
in
 S
tu
di
es
 II
, I
II,
 a
nd
 IV
 h
ad
 a
ls
o 
be
en
 
in
te
rv
ie
w
ed
 d
ur
in
g 
th
e 
di
ag
no
st
ic
 p
ro
ce
du
re
. A
lc
oh
ol
 c
on
su
m
pt
io
n 
du
rin
g 
th
e 
da
ys
 p
re
ce
di
ng
 e
xa
m
in
at
io
ns
 w
as
 n
ot
 a
sk
ed
.  
N
A
=
no
t 
av
ai
la
bl
e
48
4. MATERIALS AND METHODS
4.2 Assessment of depression 
In the auditory ERP study (Study IV), a specialist in psychiatry re-
evaluated the psychiatric records of the 72 CSE patients (84% of the 86 
patients in the study group) who had during the diagnostic procedure 
at FIOH undergone a psychiatric assessment. Patients who at the time 
of ERP recording had fulﬁ lled the diagnostic criteria of current major 
depressive episode according to DSM-IV (184) numbered 21. Patients 
who had reported depressive symptoms not fulﬁ lling DSM-IV criteria 
were 11, and those without depressive symptoms were 40. In the mul-
timodal ERP study, the current mood of the patients and controls was 
screened by the Depression Scale (DEPS) (231).
4.3 Cognitive parameters
In the multimodal ERP study, the patients and controls performed 
computerized cognitive tests from the Cambridge Neuropsychologi-
cal Test Automated Battery (CANTAB®, Cambridge Cognition Ltd, 
UK), measuring working memory performance, eﬃ  ciency of learning, 
and various aspects of attention. Th e test battery included Spatial Span 
(SSP), Intra-Extra Dimensional Set Shift (IED), Rapid Visual Informa-
tion Processing (RVP), Spatial Working Memory (SWM), and Paired 
Associate Learning (PAL) (232–234). Verbal task instructions were 
standardized, and all assessments were done by the same trained inves-
tigator. After the ERP recording, all subjects performed the tasks in the 
same order via a 15-inch touch-screen in a quiet, semi-darkened room. 
Due to technical failure, two controls missed taking the cognitive tests 
and thus the ﬁ nal number of controls was 11. 
4.4 Assessment of exposure
In Study I, which characterizes the work tasks and solvent exposure 
of CSE patients, an industrial hygienist analyzed the lifetime solvent 
exposure of each patient, identiﬁ ed and classiﬁ ed the main solvents in 
the exposure, and categorized the main exposure-work according to a 
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list of 20 common work tasks with solvent exposure. Data were based 
on the detailed work and exposure description in the patient records.
In all ﬁ ve studies, we used two indices of long-term solvent exposure. 
Th e Duration of occupational solvent Exposure in Years (DEY) is the 
actual time at exposure-work excluding periods without solvent expo-
sure, e.g., during unemployment or disability leave. OELY takes into 
account also the intensity of lifetime exposure. Estimation of OELY is 
based on a work description including ventilation and use of personal 
protective devices, duration of exposure work, and characterization of 
solvents and exposure levels. If measurements at workplaces were unavail-
able, we used hygienic data from similar workplaces, gathered over the 
years in the FIOH’s Register of Industrial Hygiene Measurements. One 
OELY is equivalent to working eight hours a day for one year with the 
solvent exposure at the Finnish Occupational Exposure Limit (OEL). 
Th e equation OELY = ∑iCi ti, where Ci is the average solvent exposure 
level in ith work task expressed as a percentage of the Finnish OEL of 
1981, and ti is the total duration in years of the work in the ith task. 
For example, a patient had been working as a painter for 37 years, dur-
ing 1955–1991. He had been doing active painting for 3 hours per day, 
11 months per year. His exposure had been mainly to toluene, xylene, 
alcohols, ketones, ethyl acetate, and gasoline. During 1955–1986, the 
use of solvent-based paints had been 10 to 20 liters per day, but during 
1987–1991 only one liter per day. During 1955–1984 (30 years) the 
exposure was at the level of OEL, and the solvent exposure level was 
3 ÷ 8 x 1.0 OEL = 0.375 OEL. Measurements at his workplace revealed 
that during 1985–86 (2 years) solvent exposure level was 40% of the 
OEL. Th e solvent exposure level was thus 3 ÷ 8 x 0.4 OEL = 0.15 OEL. 
During 1987–1991 (5 years) the proportion of solvent-based paints of 
all paints was only 10%. Th e solvent exposure level was 0.10 x 3 ÷ 8 
x 0.4 OEL = 0.02 OEL. Th e equation of OELY is 11 ÷ 12 (30 years x 
0.375 OEL + 2 years x 0.15 OEL + 5 years x 0.02 OEL) = 10.7 OELY.
In the EEG study (III), we also used the ratio of OELY and DEY as 
a measure of relative intensity of exposure. 
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4.5 Assessment of incidence
Th e Finnish Job-Exposure Matrix (FINJEM) provides information 
on the number of exposed workers in Finland by occupation, agent, 
and level of exposure (235). To estimate the incidence of CSE in the 
solvent-exposed workforce, we compared the number of CSE cases to 
the number of (1) solvent-exposed workers and (2) workers exposed at 
high solvent exposure-levels (> 50% of the occupational exposure limit, 
OEL) during 1960–2006. Th e FINJEM data was classiﬁ ed according to 
agent, i.e., solvents classiﬁ ed into four groups: (1) aliphatic and alicyclic 
hydrocarbons, (2) aromatic hydrocarbons, (3) chlorinated hydrocarbons, 
and (4) other organic solvents (alcohols, ketones, esters, ethers, carbon 
disulﬁ de, and glycol compounds). Th e total number of those employed 
in Finland, in diﬀ erent provinces, and in diﬀ erent work tasks came from 
the national workforce survey (236). 
4.6 Magnetic resonance imaging
MRI of the CSE patients had been performed with a 1.0 or 1.5 Tesla 
scanner (Siemens Magnetom, Erlangen, Germany) between 1991 and 
2001 as a part of their diagnostic procedure. Transaxial T2 - (TR 2200ms, 
TE 80 ms) and PD- (TR 2200 ms, TE 13 ms) or T2 - (TR 4000 ms, TE 99 
ms) and FLAIR- (TR 9999 ms, TE 105 ms, TI 2500), as well as coronal 
T2 - or T1 -weighted (TR 600 ms, TE 15 ms) images, had been produced. 
Th e slice thickness had been 5 mm for transaxial and 4 mm for coronal 
sections and the number of slices 19–20 on every pulse sequence. 
In Study II, the MRI scans were independently re-evaluated by two 
experienced neuroradiologists, blinded to the original MRI assessment, 
exposure data, and results of other examinations. Periventricular (cap-
ping and lining) and deep white matter hyperintensities were analyzed 
according to a validated rating system: small (<5 mm) and large (6–10 
mm) focal lesions and focal (11–26 mm) and diﬀ use (>26 mm) conﬂ u-
ent lesions (237). White matter hyperintensities in the corpus callosum, 
cerebellum, and brain stem, as well as hypointensities in basal ganglia and 
thalamus were recorded. No more than ﬁ ve small (<5 mm) focal deep 
white matter hyperintensities, small periventricular caps, and thin lining 
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were regarded as normal. Brain atrophy in 13 brain areas (cortical and 
central atrophy in frontal, parietal, temporal, and occipital brain areas, 
and in the cerebellum as well as atrophy in the vermis, brainstem, and 
corpus callosum) was rated visually in comparison to standard images 
which show a series of brain scans of successively increasing ventricular 
size and widening sulci from normal (grade 1) to severe brain atrophy 
(grade 8) (238). Ventricular size and sulcal width of more than grade 4 
were considered abnormal. An atrophy sum-score reﬂ ecting the extent 
of atrophy was calculated for each CSE patient by giving one point for 
atrophy in every single brain area. Th e MRI ﬁ nding was considered 
positive if both the neuroradiologists agreed. If they disagreed, the lower 
rating was chosen. 
4.7 Electroencephalography
EEG had been recorded between 1994 and 2000 as a part of the patients’ 
diagnostic procedure. Th e subjects were sitting, eyes closed, in an arm-
chair in a quiet and dim room, but had been instructed to stay awake. 
Electrodes were attached to the scalp according to the international 
10–20 system (Fig. 6).
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Fig. 6. Location and nomenclature of EEG electrodes according to the inter-
national (A) 10–20 system and (B) 10–10 system. F = frontal, Fp = frontal 
polar, T = temporal, C = central, P = parietal, O = occipital. Electrodes are 
numbered odd on the left side of the brain and even on the right side of the 
brain. Electrodes on the center (midline) are appended with the letter z.
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Two additional electrodes were an Fpz electrode (between the Fp1 
and Fp2 electrodes) and an Oz electrode (between the O1 and O2 elec-
trodes). Recording was performed with Cadwell Spectrum 32 equipment 
with 21 channels. Th e signal was ﬁ ltered with a 70-Hz low-pass ﬁ lter 
and a 50-Hz notch ﬁ lter. Th e visual interpretation, choice of epochs, and 
quantitative analyses were performed oﬀ -line with a Cadwell RDC-32 
reading station with the Neurometrics program. For the quantitative 
analysis, 24 epochs lasting 2.5 seconds each (60 sec total) were gathered. 
Th e frequency band analyzed was divided into the delta (1.5–3.5 Hz), 
theta (3.5–7.5 Hz), alpha (7.5–12.5 Hz), and beta band (12.5–25.0 Hz). 
In monopolar montages (A1A2 as reference), absolute power values had 
been analyzed in these bands in all 21 channels. Th e total power values 
were summed from the power values of delta, theta, alpha, and beta 
bands. Th e number of variables had been reduced by calculating regional 
means from the original variables: the frontal region (Fp1, Fp2, Fpz, F3, 
F4, and Fz), temporal (T3, T4, T5, and T6), centroparietal (C3, C4, 
Cz, P3, P4, and Pz), and occipital region (O1, O2, and Oz). Finally, a 
clinical neurophysiologist provided his clinical statement based on the 
statistical analyses of these 20 EEG variables. EEG was performed in 
the same way with the laboratory and age-matched controls. In Study 
III, the data of these 20 EEG variables from all the patients and controls 
were collected and analyzed. 
4.8 Auditory event-related potentials 
Th e auditory ERP recording in Study IV had been performed on the 
patients between 1994 and 2002 as one part of their clinical diagnostic 
procedure. A Cadwell Spectrum 32 system was used to perform the 
oddball paradigm. Tones were presented with a varying interstimulus 
interval (1.72–1.96 s) binaurally at a 70 dB sound pressure level (a 10 
ms rise time, 30 ms plateau time, and 10 ms fall time). Th e frequency 
was 1000 Hz for standard tones and 2000 Hz for target tones. Two 
256-trial blocks were presented, each containing 64 (25%) target stimuli 
in random order. Two consecutive 256 trial blocks had been carried out 
to control repeatability of the recording. 
All subjects had been examined sitting in a chair while awake with 
eyes closed. Th e research technician observed the alertness and perform-
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ance of the subject; in cases with artefacts, recording was momentarily 
interrupted. Before recording, an example of the task was presented to 
ascertain that all the subjects could easily discriminate the target from 
the standard tones. Th e subjects were asked to count silently the number 
of target stimuli.
Th e event-related potential (bandpass 0.5–80 Hz) was recorded at 
the Pz electrode site (International 10–20 system, see Fig 5). Linked 
ears (A1A2) served as a reference. Waveforms were averaged on-line 
by the Cadwell Spectrum 32 system, which also controlled the quality 
of the response and rejected artefacts: Trials in which EEG exceeded 
± 80 μV were automatically rejected on-line. Th e analysis time was 650 
ms including a 50 ms pre-stimulus baseline. Th e mean responses were 
digitally ﬁ ltered (6 Hz lowpass), and responses from both trial blocks 
were compared visually to ensure repeatability. Only waveforms present 
in both stimulus blocks were considered adequate responses for the 
analyses. Th e amplitude of P300 was measured relative to the 50 ms 
pre-stimulus baseline and the latency from the onset of the stimuli. Th e 
auditory ERP had been performed in the same way for the laboratory 
and age-matched controls. In Study IV, data on the ERP variables from 
all the patients and controls were collected and analyzed.
4.9 Multimodal event-related potentials 
In the multimodal ERP study (Study V), we used three tasks: (1) an 
auditory “oddball” (AUD) (see Fig. 2), (2) a visual detection (VIS), and 
(3) a recognition memory (MEM) task. AUD consisted of 515 auditory 
stimuli (presented for 50 ms with a rise and fall time of 10 ms, 60 dB 
over auditory threshold) presented through headphones (Telephonics 
TDH-39P). Th e frequent standards (1000 Hz, 80% probability) and the 
infrequent deviants (1500 Hz, 20% probability) were presented randomly 
so that at least two frequent standards appeared between the infrequent 
targets. Th e sequence was the same for each trial. Th e inter-tone interval 
was 700 ms. Th e subjects were instructed to push the button with their 
left hands as fast as possible when hearing the targets. 
MEM was a modiﬁ ed matching-to-sample version of the Sternberg 
paradigm (239). Th ree black letters randomly selected from the English 
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alphabet were presented on a light gray background on a 19-inch com-
puter monitor for 2300 ms, followed immediately by a single target letter 
presented for 2000 ms. Th e subjects were instructed to push the button 
with their right hand as fast as possible only when the target had been 
included in the previous set (Fig. 7). Th e inclusion probability in the 
90 trials was 50%, and the target was equally often at the ﬁ rst, second, 
and third position of the three-letter set.
VIS was identical with the memory task in structure and presentation 
times. Instead of three letters, three symbols “XXX” were presented on 
the monitor. Th e target symbol was either an “O” (inclusion, probability 
50%) or an “X” (exclusion). Th e subjects were instructed to push the 
button with their right hand as fast as possible only when seeing the 
target “O” (Fig. 7).
Fig. 7. (A) In the memory task (MEM) of the multimodal ERP study, three 
letters were presented and followed immediately by a single target letter. 
The subjects were instructed to push the button only when the target had 
been included in the previous set. (B) In the visual tasks (VIS), three symbols 
“XXX” were presented. The target symbol was either an “O” or an “X”. 
The subjects were instructed to push the button only when seeing the tar-
get “O”. =response with right hand.
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Th e tasks were performed separately and in combination with each 
other (dual-task condition). In dual tasks, the stimuli of diﬀ erent mo-
dalities were presented concurrently so as to ensure an even distribution 
of auditory over visual stimuli to preclude any time-locked interference 
between the responses.
Th e study protocol consisted of seven task conditions in the follow-
ing order: 1) AUD, 2) a training set for MEM, 3) MEM, 4) a training 
set for a dual task with AUD and MEM, 5) a dual task with AUD and 
MEM, 6) VIS, and 7) a dual task with AUD and VIS. 
Each subject was sitting in a comfortable armchair 1.80 m from the 
screen in a quiet, semi-darkened room. During task performance, the 
research technician ensured that each subject had understood the tasks 
and stayed alert. In task conditions 1, 6, and 7, if the participants gave an 
incorrect response to the ﬁ rst three deviants, the performance was inter-
rupted and the task explained again. In all tasks, reaction time, number 
of misses (no response in two seconds), and EEG activity were recorded.
Stimulations and EEG recording were done with a Cognitrace EEG/
ERP system (Version 3.3, ANT, Enschede, Holland). EEG was recorded 
with active shielded 64-channel EEG caps with an electrode layout fol-
lowing the international 10-10 system (see Fig. 5) (Waveguard, ANT; 
electrode material Ag-AgCl) and with a DC-ampliﬁ er (REFA-64, ANT) 
using a sampling frequency of 512 Hz. Electro-oculography (EOG) and 
electrocardiography (ECG) were also recorded. Timing of the diﬀ erent 
stimuli and of the responses was recorded together with the EEG.
Pre-processing and analysis of the recordings was done with ASA 
software (Version 4.6.2.0, ANT). EEG was ﬁ ltered with a bandpass of 
0.3–30 Hz (12 dB/octave rollof ). Blink artefacts were removed by an al-
gorithm based on spatial ﬁ ltering (240). Th e manually selected prototypes 
of blinks per recording numbered least ten. After artefact correction, the 
data were remontaged with a reference set to linked mastoids (M1+M2). 
Only data from electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4, Pz, P3, 
P4, O1, and O2 were retained for further analysis. Remaining artefacts 
were excluded with an amplitude criterion of ± 75 μV before calculation 
of the averaged waveforms. Th e continuous EEG data was transformed 
oﬀ -line to 1100-ms epochs, starting 100 ms before the onset of each 
stimulus. Finally, the averaged waveforms were baseline corrected by the 
100 ms preceding the stimulus as the baseline. 
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Amplitude and latency of P300 elicited by the auditory and visual 
stimuli were measured as the most positive waveform around 300 ms. 
In MEM, P300 was measured from the waveform elicited by the target 
letter included in the previously set of three letters. In VIS, P300 was 
measured from the waveform elicited by all “O” stimuli. Th e results of 
the automated peak detection were veriﬁ ed manually and corrections 
performed when necessary.
4.10 Statistical methods
Study I
Th e numbers and proportions of CSE cases and cases referred to FIOH 
as well as the measures of location and dispersion of the variables were 
calculated with Microsoft Oﬃ  ce Excel 2007 (Microsoft Corp., Redmond, 
WA, USA). SAS 8.2 software (SAS Inc., Gary, NC, USA) served in the 
linear regression analyses and MedCalc Software Version 9.3.9.0 (Med-
Calc Software, Mariakere, Belgium) in the comparison of proportions 
with the Chi-square test.
Study II
In the MRI study, statistical analyses were performed with SAS 8.2 
software. To study the association between MRI ﬁ ndings and solvent 
exposure we used logistic regression. Th e potential explanatory eﬀ ects 
describing the exposure were DEY and OELY. Other factors incorporated 
in the analyses included patient age, amount of alcohol consumed, and 
number of cardiovascular risk factors. 
Study III
In the EEG study, statistical analyses were performed with the GLM 
(General Linear Models) procedure in SAS 8.2 software. Because the 
distributions of absolute power values were right-skewed, we used 
logarithmic transformation. Th e models were adjusted for age. We used 
the traditional analysis of covariance which assumes that all categories 
have the same age dependence. No interactions of age and category 
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were detectable. Adjusted means and their 95% conﬁ dence limits were 
converted back to a non-logarithmic scale.
Study IV
In the auditory ERP study, the P300 latencies and amplitudes of CSE 
patients and laboratory controls were compared by use of an analysis of 
covariance with adjustment for age. Degrees of freedom were adjusted 
(Greenhouse-Geisser) when appropriate. Th e P300 values and neu-
ropsychological performance between the study groups were compared 
by the independent measures t-test. Th e homogeneity of variances was 
evaluated with Levene’s test. Th e associations of alcohol consumption, 
neuropsychological test results, and exposure indices with P300 values 
were studied by Spearman rank order correlation analysis. Comparisons 
between the subgroups of CSE patients were done with the independent 
samples t-test. In follow-up comparison of P300, we used the paired 
samples t-test. All statistical tests were two-tailed, and the level for sig-
niﬁ cance was set at p < 0.05. Th e analyses were performed with the SPSS 
for Windows, version 12.0 (SPSS Inc., Chicago, IL, USA).
Study V
Th e comparisons of P300 values, task performance, and results in neu-
ropsychological tests between CSE patients and matched controls were 
made by the independent measures t-test. Th e homogeneity of variances 
was evaluated with Levene’s test. All statistical tests were two-tailed with 
the level of signiﬁ cance set at p < 0.05. Th e correlation of ERP values 
with neuropsychological test results was studied by Spearman rank or-
der correlation analysis. Th e analyses were performed with the SPSS for 
Windows, Version 17.0. Missing amplitude values, i.e. when no P300 
component was recognizable, were replaced with value zero. Latency 
values were not replaced, and thus the number of subjects was reduced 
in the AUD+VIS condition and no statistical testing was performed for 
the AUD+MEM condition. 
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5.1 Cases with suspected chronic solvent 
encephalopathy 
Workers referred to FIOH during 1995–2005 for a suspicion of CSE 
numbered 425. Th e annual number of referrals (mean 38.6, range 26–47, 
SD 6.15) has remained rather constant (Fig. 8). 
Fig. 8. Cases referred to FIOH with a suspicion of CSE annually, 1995–2005 
(n=425). Each column’s black segment represents the proportion of cases 
not diagnosed with CSE in that year but during following years.
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Of the 425 referred cases, CSE was eventually diagnosed in 103 
(24%). Comparing the time periods 1995–1999 and 2000–2005, the 
proportion of those diagnosed among referred cases declined from 38 
to 15% (Fig. 8). 
During 2002–2004, the referrals to FIOH (n=128) had come from 
occupational health care units in 71% of the cases, from a neurological 
outpatient clinic of a central or district hospital in 8%, from some other 
outpatient clinic in 10%, and from a rehabilitation unit in 8%. Th ree 
cases were found in a study project of construction painters at FIOH 
(14). Of the 128 cases, CSE diagnosis was rejected in 109 (85%). Th e 
most common reason: Of 109 cases in 47 (43%) the clinical picture or 
neuropsychological test proﬁ le was not suggesting CSE. Of these 47 
cases, in 31 (66%), lifetime solvent exposure was considered insuﬃ  cient 
to cause permanent CNS disturbances. In cases with multiple confound-
ing etiologies, all with suﬃ  cient solvent exposure, the clinical picture 
or neuropsychological test proﬁ le or both may have suggested CSE, but 
even after follow-up and adequate treatment of confounding factors such 
as excessive alcohol consumption, depression, sleep apnea, or chronic 
pain, it was impossible to show that occupational solvent exposure was 
the main etiology (Table 5).
Table 5. Major reasons for rejection of chronic solvent 
encephalopathy diagnoses in suspected cases during 2002–2004 
(n=109).
n (%)
Clinical picture or neuropsychological test profile did not suggest CSE 47 (43)
Multiple confounding etiologies 22 (20)
Depression 21 (19)
Non-occupational brain disease 10 (9) 
Psychiatric disease (other than depression) 4 (4)
Alcohol abuse 3 (3)
Sleep disorder 2 (2)
Of the cases referred to FIOH during 2002–2004, CSE was even-
tually diagnosed, not the year in which they were referred, but during 
the following years, in 19 of 128 (15%) cases; 14 (74%) of them due 
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to CSE were unable to perform any work. Of the ﬁ ve patients with re-
sidual work ability, four were never employed and were ﬁ nally granted 
disability pensions. Only one patient continued in the same work but 
at lower exposure levels. 
5.2 Cases with chronic solvent encephalopathy 
During 1995–2007, cases diagnosed at FIOH with CSE as an occupa-
tional disease due to long-term solvent exposure numbered 128, includ-
ing 12 women. Th e annual number of new cases diminished from 18 
to 3 (Fig. 9). Most of the cases were diagnosed in southern and western 
Finland (Fig. 10). 
Fig. 9. Numbers of occupational chronic solvent encephalopathy cases in 
Finland diagnosed annually during 1995–2007 (n=128). 
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Fig. 10. Numbers of occupational chronic solvent encephalopathy cases 
during 1995–2007 and numbers of those employed in the five provinces of 
Finland. 
Patients’ mean age at diagnosis was 52.8 (median 54, range 35–73, 
SD 6.1); the majority (118 of 128) were ≥ 45. In classifying the cases ac-
cording to the main work task, the youngest were the 11 (mean age 49.5) 
doing reinforced plastic lamination and the oldest were the 26 (mean 
age 54.7) construction painters. During 1995–2007, the patient age has 
increased annually by 0.6 years (p=0.0002, linear regression analysis). 
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5.3 Incidence of chronic solvent 
encephalopathy 
Comparing the annual number of CSE cases to the number of employed, 
the incidence of CSE has decreased between 1995 and 2007 from 8.6 
to 1.2 / million employed per year. During the study period, the mean 
incidence in diﬀ erent provinces ranged from 3.3 to 4.9 cases per million 
employed (mean 4.0), the lowest being in Lapland and the highest in 
Oulu Province. 
Compared to the number employed in various work tasks, the average 
annual incidence of CSE during 1995–2007 was highest in wooden-
surface ﬁ nishers and in industrial, metal, or car painters, followed by 
ﬂ oor layers and lacquerers (Table 6). Despite the second highest number 
of CSE cases in construction painting, this ﬁ eld was not among the tasks 
with the highest incidence ﬁ gures.
Table 6. The main work tasks of the 128 chronic solvent 
encephalopathy (CSE) patients and incidence of CSE in relation to 
those employed
 
n (%)a Incidenceb
Industrial, metal, or car painters 48 (38) 0.8
Construction painters 26 (20) 0.2
Printing-trade workers 12 (9) 0.3
Floor layers and lacquerers 11 (9) 0.7
Reinforced plastic laminators 11 (9) 0.3
Wooden surface finishers 9 (7) 0.9
Gluers 9 (7) NA
Motor vehicle cleaners 8 (6) NA
Other industrial workers 4 (3) NA
Degreasers 4 (3) NA
Rubber product workers 2 (2) 0.1
Footwear workers 2 (2) < 0.1
Gasoline handlers 2 (2) < 0.1
Vehicle and machine mechanics 2 (2) NA
Maintenance and repair workers in industry 2 (2) NA
Producers of paint, lacquer, and printing inks 2 (2) NA
Laundry workers (dry cleaners) 1 (1) 0.1
Paint removers 1 (1) NA
a  Some had more than one main work task
b  Average incidence during 1995–2007: CSE cases / 1000 workers in the work task 
under consideration according to the National Workforce Survey
NA=not available
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Comparing the numbers of CSE cases, classiﬁ ed by main solvent 
exposure, with the numbers of exposed workers by agent in Finland, as 
retrieved from FINJEM, the incidence of CSE during 1995–2006 was 
highest in workers with exposure to aromatic hydrocarbons (decreased 
from 1.2 to 0.3 / 1 000 per year) and the group of other organic solvents 
(0.8–0.2 / 1 000 per year) (Table 7a). Compared with the number of 
workers exposed to levels above 50% of OEL, the incidence of CSE 
during 1995–2006 was highest in workers with exposure to aliphatic 
hydrocarbons (66.7–22.2 / 1 000 per year) (Table 7b).
Table 7a Incidence of chronic solvent encephalopathy (CSE) in Finland 
by solvent exposure
 
1995–1997 1998–2000 2001–2003 2004–2006
Aliphatic and alicyclic 
hydrocarbons
CSE casesa 8 8 6 2
Exposed workersb 12 000 10 000 10 000 11 000
Incidencec 0.2 0.3 0.2 0.1
Aromatic hydrocarbons
CSE cases 43 33 25 12
Exposed workers 12 000 14 000 14 000 14 000
Incidence 1.2 0.8 0.6 0.3
Chlorinated hydrocarbons
CSE cases 5 9 2 2
Exposed workers 5 100 3 000 2 400 2 400
Incidence 0.3 1.0 0.3 0.3
Other organic solventsd
CSE cases 25 28 23 8
Exposed workers 11 000 12 000 10 000 11 000
Incidence 0.8 0.8 0.8 0.2
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Table 7b Incidence of chronic solvent encephalopathy (CSE) in Finland 
by solvent exposure of the Finnish work force at levels >50 % of 
Occupational Exposure Limit Years 
1995–1997 1998–2000 2001–2003 2004–2006
Aliphatic and alicyclic 
hydrocarbons
CSE casesa 8 8 6 2
Exposed workersb 120 90 30 30
Incidencee 22.2 29.6 66.7 22.2
Aromatic hydrocarbons
CSE cases 43 33 25 12
Exposed workers 1 700 1 300 1 300 1 200
Incidence 8.4 8.5 6.4 3.3
Other organic solventsd
CSE cases 25 28 23 8
Exposed workers 4 000 4 500 3 700 4 100
Incidence 2.1 2.1 2.1 0.7
a  number of CSE cases with main exposure to the solvent group under consideration 
during the 3-year period
b  data based on the Finnish Job-Exposure Matrix
c  CSE cases annually / 1 000 workers exposed to the solvent group under considera-
tion 
d  alcohols, ketones, esters, ethers, carbon disulfide, and glycol compounds
e  CSE cases annually / 1 000 workers exposed at levels >50 % of OEL to the solvent 
group under consideration per year
5.4 Exposure-work of chronic solvent 
encephalopathy cases 
CSE has occurred in a variety of work tasks, the most common being 
industrial, metal, or car painting, tasks entailing predominantly spray 
painting, and construction painting (Table 6). During 1995–2000, 
the number and proportion of all CSE cases have decreased among 
industrial, metal, or car painters: from 32 (40%) to 16 (34%) as well as 
among construction painters: from 18 (22%) to 8 (17%). Th e number 
of printers, ﬂ oor layers and lacquerers, and reinforced plastic laminators 
remained constant at six, but their proportion of all CSE cases increased 
from 6 to 13%. 
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5.5 Solvent exposure of the chronic solvent 
encephalopathy cases
According to FINJEM, the number of workers with exposure to aliphatic 
hydrocarbons, chlorinated hydrocarbons, and other organic solvents (al-
cohols, ketones, esters, ethers, carbon disulﬁ de, and glycol compounds) 
decreased from the 1960s to the 1990s about 60% and with exposure 
to aromatic hydrocarbons, about 43%. Th e proportion of workers ex-
posed to levels >50% of OEL has decreased among those with exposure 
to aliphatic (from 1.9 to 0.6%) and to aromatic hydrocarbons (from 18 
to 11%) but increased among those exposed to other organic solvents 
from 12 to 37%. 
Th e mean DEY of the patients was 28.4 (median 28, S.D. 8.3, range 
7–49), and the mean OELY, 10.5 (median 9, S.D. 4.3, range 4–26). CSE 
cases with DEY below 10 numbered 2, whereas in most cases, among 
128, for 112 (88%), DEY was ≥ 20. Th e lowest mean DEY (23.8) was 
among the 11 reinforced plastic laminators who also had the highest 
mean OELY (14.1). Th e mean DEY (32.9) of the 26 construction paint-
ers was the highest, and their mean OELY the lowest (10.0) (Fig. 11). 
Fig. 11. Mean duration of occupational solvent exposure in years in the five 
most common work tasks of chronic solvent encephalopathy patients in Fin-
land during 1995–2007.The black segment in the column represents mean 
occupational exposure limit years (OELY).
Industrial
painters
(n=48)
Construction
painters
(n=26)
Laquerers
and floor
layers
(n=11)
Painting-
trade
workers
(n=12)
Reinforced
plastic
lamination
(n=11)
67
5. RESULTS
OELY was less than six in four patients. Two of them, a process worker 
(DEY 7, OELY 4) and a supervisor (DEY 19, OELY 5) with exposure 
peaks mainly to xylene, n-propanol, and possibly to methylene chloride, 
shared the same workplace in the pharmaceutical industry. In its entirety, 
the lifetime exposure of another supervisor in industrial painting with 
exposure to mainly xylene (DEY 23, OELY 5) was considered suﬃ  cient 
to cause CNS disturbances. Th e exposure levels of a gluer in furniture 
manufacture (DEY 9, OELY 4.5) were considered relatively low, but skin 
exposure had been estimated as considerable, and previous reports from 
similar work tasks suggest exposure levels higher than these. 
During 1995–2007, DEY increased annually by 0.8 (p=0.0003, lin-
ear regression analysis), but OELY – an estimate of intensity of lifetime 
exposure – remained similar (p=0.92). 
Th e most common main solvent exposure, in 100 (78%) of 128 
cases, had been to aromatic hydrocarbons, especially to solvent mixtures 
containing toluene and xylene (Table 8). Th e main exposure in 85 (66%) 
cases included other organic solvents (alcohols, ketones, esters, ethers, 
carbon disulﬁ de, and glycol compounds), in 60 (47%) mineral spirits, 
in 24 (19%) aliphatic hydrocarbons, and in 19 (15%) cases chlorinated 
hydrocarbons (Table 8).
Th e most common exposure of construction painters, in 25 (96%) 
of 26 cases, was to mineral spirits, whereas all the 48 industrial, metal, 
or car painters had been exposed to mixtures of aromatic hydrocarbons; 
the most common component, in 44 of 48 cases (92%), was xylene. 
Among 11 who did reinforced plastic lamination, the main exposure in 
10 (91%) was to styrene (Table 8).
Most of the 128 patients, 118 (92%), had been exposed to mixtures 
of solvents. Patients with single solvent exposure had been exposed to 
styrene, toluene, xylene, trichloroethylene, perchloroethylene, or ethyl 
acetate. 
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Table 8. Main solvent exposure of the 128 chronic solvent encephalopathy cases 
and of the cases performing the ﬁ ve most common work tasks.  
 All 
patientsa
Industrial, 
metal, 
or car 
paintingb
Con-
struction 
paintingb
Printing 
workb
Floor 
laying and 
lacqueringb
Reinforced 
plastic 
laminationb
Number of patients n (%) 128 (100) 48 (38) 26 (20) 12 (9) 11 (9) 11 (9)
Solvents
Aliphatic hydrocarbons 24 (19) 2 (4) 2 (8) 2 (17) 6 (55) 1 (9)
n-hexane 14 (11)
Other 22 (17)
Aromatic hydrocarbons 100 (78) 48 (100) 17 (65) 6 (50) 8 (73) 10 (91)
Toluene 68 (53) 29 (60) 10 (38) 5 (42) 7 (64) 3 (27)
Xylene 65 (50) 44 (92) 12 (46) 1 (8) 4 (36) 4 (36)
Styrene 22 (17) 14 (29) 1 (4) 0 (0) 2 (18) 10 (91)
Benzene 2 (2) 0 (0) 0 (0) 2 (17) 0 (0) 0 (0)
Other 11 (9) 7 (15) 0 (0) 1 (8) 0 (0) 0 (0)
Mineral spiritsc 60 (47) 27 (56) 25 (96) 4 (33) 3 (27) 2 (18)
Chlorinated 
hydrocarbons
19 (15) 4 (8) 3 (12) 2 (17) 0 (0) 3 (27)
Trichloroethylene 7 (5)
Perchloroethylene 4 (3)
Trichloroethane 3 (2)
Methylene chloride 8 (6)
Other 1 (1)
Other organic solvents 85 (66) 35 (73) 5 (19) 10 (83) 8 (73) 4 (36)
Alcohols
Methanol 1 (1)
Ethanol 17 (13)
Propanol 18 (14)
Butanol 34 (27)
Ketones
Acetone 33 (26)
Methyl ethyl ketone 9 (7)
Other 7 (5)
Esters
Ethyl acetate 29 (23)
Other 34 (27)
Ethers 5 (4)
Glycol compounds 25 (20)
Gasoline 1 (1)
Organic nitrogen 
compounds
1 (1)
a  118 of 128 cases had their main exposure to more than one solvent
b  only main exposure classes included except for aromatic hydrocarbons
c  mainly White spirit or Stoddard Solvent, a mixture of aliphatic hydrocarbons with a maximum of 
25% of aromatic hydrocarbons
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5.6 Magnetic resonance imaging 
Of 71 CSE patients, the brain MRI of 27 (38%) was classiﬁ ed as abnor-
mal – as atrophy or abnormal white matter ﬁ ndings or both. Of these 
27 patients, 10 had both atrophy and abnormal white matter ﬁ ndings. 
Of 71 patients, 17 (24%) had brain atrophy in any brain area, with the 
most common locations being for 9 in the cerebellar cortex and for 7 in 
the vermis. Only one patient had vermian atrophy without cerebellar at-
rophy. Central cerebellar atrophy was present in four and corpus callosum 
atrophy in three patients. Th e majority of the cerebral atrophy ﬁ ndings 
were located in the frontal and parietal brain areas (ﬁ ve cases each). Th e 
mean atrophy score reﬂ ecting extent of atrophy was 2.6 (range 1–8). 
Brain atrophy ﬁ ndings are shown in Fig. 12. Of 71 patients, abnormal 
white matter hyperintensities were visible in 20 (28%), for whom the 
most prevalent abnormalities were small (in 14) and large (in 12) focal 
lesions in the deep white matter. Focal conﬂ uent lesions were present in 
three and diﬀ use conﬂ uent lesions in one patient. White matter lesions 
were visible in the brainstem of seven patients. Examples of white matter 
ﬁ ndings are in Fig. 13. 
Cerebral and cerebellar brain atrophy was, unrelated to age, associated 
with duration of exposure (Pe 0.009 and 0.017, respectively). Patients 
whose exposure duration had been 10 years longer were from three to four 
times more likely to have atrophy (1.14010=3.7, 1.11610=3.0) than were 
those with shorter exposure. Periventricular and brainstem white matter 
hyperintensities were related to age (Pe 0.04 and 0.03, respectively), and 
vermian atrophy to alcohol consumption (Pe 0.02).
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Fig. 12. Coronal (A) and sagittal (B) sections of the brain MRI of a 54-year-
old painter revealed in T1 -weighted images central and cortical brain atro-
phy in frontal, parietal, and occipital brain areas and in the cerebellum and 
vermis. Atrophy sum score was 6. The patient had hypertension and hyperc-
holesterolemia, he was a smoker, and his average alcohol consumption was 
480 g/month. He had been exposed mainly to White spirit and xylene for 40 
years (OELY 10).
(A)
(B)
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Fig. 13. Axial sections of the brain MRI of a 58-year-old supervisor in the 
cleaning and degreasing industry reveal small and large focal lesion in deep 
white matter and large frontal capping and irregular lining in periventricular 
white matter in T2 -weighted images. The patient had been exposed mainly 
to trichloroethylene for 43 years (OELY 8), he had no other diseases, he did 
not smoke, and his average alcohol consumption was 39 g/month.
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5.7 Quantitative electroencephalography
In the QEEG study, the power of the theta band in the frontal area was 
1.6 times higher in the CSE patient group than in the laboratory control 
group (mean 4.7 (μV)2, 95% Cl 4.0–5.5 versus mean 3.0 (μV)2, 95% Cl 
2.6–4.2; p=0.019). Compared to the age-matched control group, CSE 
patients had lower beta power in the centroparietal area (mean 6.3 (μV)2, 
95% Cl 5.6–7.1 versus mean 4.8 (μV)2, 95% Cl 4.1–5.7; p=0.009), but 
theta power did not diﬀ er. No diﬀ erences appeared, however, in beta 
power between CSE patients and laboratory controls. Th e age-matched 
controls had increased beta power compared to the laboratory controls 
in all except the occipital area.
Th e variables of solvent exposure (DEY, OELY, and the ratio OELY/
DEY) did not associate with the power of theta activity in the frontal area. 
A weak negative correlation emerged in the CSE patient group between 
frontal theta power and amount of reported alcohol consumption. In 
the age-matched control group, amount of reported alcohol use showed 
no association with increased theta or beta power. 
Of the 47 QEEG recordings for CSE patients, 5 (11%) were originally 
interpreted as abnormal. A diﬀ use increase in slow activity was evident 
in four recordings, and focal slow activity in the right parieto-occipital 
region in one recording.
5.8 Auditory event-related potentials
Th e P300 amplitude of the auditory ERP at Pz was smaller in the pa-
tient group (mean 7.5 μV; SD 3.6) than in the laboratory control group 
(mean 11.8 μV; SD 4.1; F(1,167)=24.4; p<0.001, 95% CI -4.4 to -1.8) 
or in the age- and education-matched control group (9.0 μV; SD 4.0; 
p=0.007, 95% CI -2.6 to -0.4). P300 latency was longer in the patient 
group (mean 358 ms; SD 28) than in the laboratory control group (mean 
339 ms; SD 19, F(1,167)=7.6, p=0.006, 95% CI 3.12 to 18.7) but did 
not diﬀ er from that of the matched control group (mean 358 ms; SD 
22; p=0.947, 95% CI -7.4 to 6.9). Age correlated negatively (-0.394, 
p<0.001) with amplitude and positively (0.417, p<0.001) with latency 
of P300.Th e exposure indices DEY and OELY did not correlate with 
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P300 amplitudes (-0.06, p=0.585) or latencies (0.009, p=0.932). Nor 
did major depression nor use of CNS medication associate with P300 
amplitudes or latencies within the patient group, nor did the amount 
of alcohol consumed in the patient’ or in the matched control groups. 
Digit symbol substitution correlated positively with P300 amplitude 
both in the patient group (0.279, p=0.011) and in the matched control 
group (0.220, p=0.026). Digits forward had a tendency to correlate 
positively with the P300 amplitude in the CSE patient group (0.20, 
p=0.074) but not in the matched control group (0.017, p=0.864). Digits 
backward correlated with amplitude in neither group. P300 latency cor-
related with none of the three neuropsychological tests in either group. 
Th e neuropsychological test results did not associate with major depres-
sion, amount of alcohol consumed, or exposure indices.
Th e follow-up group of 19 patients showed no signiﬁ cant changes in 
their P300 latency or amplitude values between their ﬁ rst and the second 
ERP recording (mean time between the recordings was 14 months, range 
10–18). Th e P300 amplitude improved in four patients, deteriorated in 
four, and remained unchanged in eleven when an at least 25% change 
in amplitude was the criterion for improvement or deterioration. No 
obvious diﬀ erence in age, DEY, or OELY appeared between patients 
with improved or deteriorated amplitude. It seemed, however, that the 
exposure-free time had been longer for the four patients with improved 
P300 amplitude than for the four patients with deteriorated amplitude. 
All the changes in P300 latency values were less than 25%. 
All the amplitudes in the CSE patient group and in the matched 
control group were classiﬁ ed as normal (i.e. age corrected mean ± 2.5 
SD) against the laboratory’s reference values. Th e latencies in 30% of 
the CSE patients and in 26% of the matched controls were classiﬁ ed 
as abnormal.
5.9 Multimodal event-related potentials
Single-task conditions
Th e P300 amplitude in the AUD task at Pz was smaller in the patient 
group (mean 4.3 μV; 95% CI 2.6 to 6.0) than in control group (mean 
7.5 μV; 95% CI 5.4 to 9.5; p=0.034). Amplitudes between groups at Fz 
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did not diﬀ er, nor did P300 amplitude diﬀ er in VIS or MEM tasks (Fig. 
14). P300 latency in any single-task condition did not diﬀ er signiﬁ cantly 
between groups. 
Dual-task conditions 
Th e auditory P300 component in the AUD+VIS condition was recog-
nizable in 3 of 11 patients and in 12 of 13 controls. In the AUD+MEM 
condition, the auditory P300 component was present in 1 of 11 patients 
and in 9 of 13 controls. 
In the entire study population, the auditory P300 amplitude in the 
single condition was smaller in the 9 subjects without recognizable au-
ditory P300 in the AUD+VIS condition (mean 4.0 μV, 95% CI 1.9 to 
6.1) than in those 15 with recognizable auditory P300 (mean 7.2 μV, 
95% CI 5.5 to 9.0; p=0.03). 
In the AUD+VIS condition, mean auditory P300 amplitude was 
decreased in the patient group (mean 1.2 μV; 95% CI 0.0 to 2.5) com-
pared to the control group (mean 4.5 μV; 95% CI 3.2 to 5.8, p=0.002). 
In the AUD+MEM condition, the results were similar: patient group 
(mean 0.5 μV; 95% CI -0.4 to 1.3) versus the control group (mean 2.6 
μV; 95% CI 1.3 to 3.9; p=0.016) (Fig. 15). 
 Between groups, the mean change in the auditory amplitude values 
from AUD to AUD+VIS (mean 3.1 μV, 95% CI 1.0 to 5.1 in patients 
and mean 3.0 μV, 95% CI 1.4 to 4.5 in controls; p=0.94) and from 
AUD+VIS to AUD+MEM conditions (mean 0.8 μV, 95% CI -0.4 to 
1.9 in patients and mean 1.9 μV, 95% CI 0.9 to 2.9 in controls; p=0.16) 
did not diﬀ er.
Th e visual P300 amplitude in the AUD+VIS or AUD+MEM condi-
tions and the P300 latency in the AUD+VIS condition did not diﬀ er 
between the groups (Fig. 14).
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Fig. 14. Median, first and third quartile, minimum and maximum of P300 amplitude val-
ues from (A) auditory targets in single condition (AUD) and dual conditions (AUD+VIS, 
AUD+MEM), (B) visual targets in single condition (VIS) and dual condition (AUD+VIS), 
(C) visual targets in MEM in single condition (MEM) and dual condition (AUD+MEM). 
AUD=auditive task, VIS=visual task, MEM=memory task, CSE= patients with chronic 
solvent encephalopathy, NC=normal controls, *=p<0.05.
Fig. 15. Auditory event-related potentials at Pz in single and dual-task conditions of (A) 
a control and (B) a CSE patient. An unrecognizable P300 response in the patient in the 
AUD+MEM dual-task condition. AUD = auditive task in single condition, AUD+VIS = 
auditive and visual tasks in dual condition, AUD+MEM = auditive and memory tasks in 
dual condition.
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Task performance
Reaction times (RT) in single-task conditions for auditory targets, visual 
targets, or responses in the memory task did not diﬀ er between groups. 
In both dual-task conditions, RT for auditory targets were longer in 
the patient group (AUD+VIS mean 525 ms; 95% CI 481 to 569 ms; 
AUD+MEM mean 606 ms; 95% CI 552 to 661ms) than in the control 
group (AUD+VIS mean 451 ms; 95% CI 425 to 476 ms; p= 0.006, 
95% CI 23 to 126; AUD+MEM mean 531 ms; 95% CI 496 to 566 ms; 
p= 0.028, 95% CI 9 to 142). RT for the visual target was prolonged in 
the patient group (AUD+ VIS mean 701 ms; 95% CI 636 to 766 ms) 
compared to that in the control group (AUD+ VIS mean 606 ms; 95% 
CI 567 to 644 ms; p= 0.017, 95% CI 19 to 172) (Fig. 16).
Response accuracy was lower in the patient group in all tasks, but the 
individual variation was large, and diﬀ erences compared to the control 
group were statistically nonsigniﬁ cant. In the neuropsychological tests, 
signiﬁ cant diﬀ erences between patients and controls appeared in the 
number of stages completed (mean 6.4, 95% CI 4.6 to 8.1 and mean 
8.6, 95% CI 8.2 to 9.1; p=0.03) and in adjusted total errors (mean 78.2, 
95% CI 39.4 to 117.0 and mean 30.6, 95% CI 19.4 to 41.9; p=0.04) 
in IED.
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Fig. 16. Median, first and third quartile, minimum and maximum of reaction time 
values for (A) auditory targets in single condition (AUD) and dual conditions (AUD+VIS, 
AUD+MEM), (B) visual targets in single condition (VIS) and dual condition (AUD+VIS), 
(C) visual targets in MEM in single condition (MEM) and dual condition (AUD+MEM). 
AUD=auditory task, VIS=visual task, MEM=memory task, CSE= patients with chronic 
solvent encephalopathy, NC=normal controls, *=p<0.05.
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6.1 Referred and diagnosed chronic solvent 
encephalopathy cases
Number of cases and incidence of CSE
Th e number and incidence of CSE cases in Finland during 1995–2007 
have clearly diminished, but the annual number of referrals to FIOH of 
cases with suspected CSE has remained rather constant. Th e number of 
CSE cases in the ﬁ ve provinces of Finland has varied, largely reﬂ ecting 
diﬀ erences in population, work force, employment, and business structure. 
Th at local incidence ﬁ gures were, however, rather equal indicates that 
knowledge and detection of solvent-exposure-related CNS adverse ef-
fects as well as screening of solvent exposed workers have spread widely 
across the country. 
Th is decrease in Finnish CSE cases during 1995–2007 is congruent 
with the trend observed during 1997–2006 in the Netherlands (180). 
Moreover, the declining trend in the incidence ﬁ gures during 1980–1998 
reported in the European survey has continued in Finland (2). Legislative 
action and cooperation between trade unions and employers has enabled 
the prevention of solvent-related adverse eﬀ ects (1,13). During recent 
last decades, the number and proportion of solvent-exposed workers and 
the levels of solvent exposure in many occupations have decreased (12). 
Nowadays, over 70% of the paints and lacquers in construction painting 
are water-soluble (10,11). Th e active replacement of chemicals by less 
harmful ones is reﬂ ected in the decreasing proportion of workers exposed 
to aliphatic, aromatic, and halogenated hydrocarbons at levels above 50% 
of OEL. Th e increased age and DEY of CSE patients between 1995 and 
2007 while OELY has remained unchanged indicates slower CSE devel-
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opment at lower exposure levels. Th e occupational solvent exposure of 
most of the CSE patients (118 of 128, 92%) diagnosed between 1995 
and 2007 had begun in the 1960s and 1970s, when workers´ solvent 
exposure was more extensive (12). As the working conditions, protection, 
and chemical composition of the products have improved since the 1980s 
(11), the number and incidence of CSE cases will presumably further 
decline, but only if the current control of solvent exposure continues. 
Th e number and incidence of CSE cases may, however, be somewhat 
higher than now reported. Th is is supported by the study on symptom 
screening in solvent- exposed populations which revealed unrecognized 
CSE cases (14). OHS usually performs the screening, which is reﬂ ected 
in the high proportion of referrals (71%) to the FIOH from OHS. In 
Finland, OHS covers nearly 90% of employees. For the self-employed – 
including many solvent-exposed workers – OHS is, however, voluntary. 
In 2004 the coverage was only 16% (241). Th is highlights the importance 
of widespread knowledge among health care professionals, also other than 
those at OHS, on the health eﬀ ects of occupational solvent exposure. 
Th e rather constant number of referrals during 1995–2005 – despite 
the decreased incidence of CSE – reﬂ ects improved awareness among 
workers and health care professionals of the health eﬀ ects of occupational 
solvent exposure and eﬀ ective symptom screening of exposed workers. 
Th e lowered threshold for recognizing symptoms indicating CSE and 
initiating investigations may have led, however, to a higher number of 
referred cases with etiologies other than solvent exposure. Th is is unsur-
prising, because the symptoms, such as sleep and mood disturbances, 
diﬃ  culties in concentration, and complaints about memory, are non-
speciﬁ c and are common in the general population. Th is is reﬂ ected in 
the high proportion of rejected cases with a clinical picture or neuropsy-
chological test proﬁ le not indicating CSE (43% of all rejected cases), 
even though the life-time solvent exposure in 34% of those cases was 
considered suﬃ  cient to cause CNS adverse eﬀ ects. Th is highlights the 
importance for the accuracy of diagnosis of profound multidisciplinary 
diagnostics with evaluation and treatment of other etiologies as well as 
thorough follow-up. Improved understanding of the characteristics of 
CSE and the relevance of sleep (219) and mood disorders (216) in the 
diﬀ erential diagnostics may have, however, resulted in an increase in 
the proportion of cases where factors other than solvent exposure are 
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considered to be the main etiology (in 44% of the rejected cases). Th is 
may in part explain the decreased number of CSE cases, although the 
diagnostic procedure and criteria per se have remained unchanged. Th e 
earlier detection of symptoms and milder cognitive disturbances upon 
diagnosis has added to the diversity of etiological factors that must be 
taken into account in the diﬀ erential diagnostics of CSE. Change in 
the evaluation of etiological alternatives is evident when considering 
the study from 1998 which reported only alcohol or drug abuse, head 
injury, and cerebrovascular or other neurological diseases as the reasons 
for exclusion from CSE diagnosis (8). 
Th e incidence of CSE in Finland during 1995–2007 fell from 8.6 to 
1.2 patients per million employed. In the previous study estimating the 
incidence of CSE in Europe, the incidence in 1997 ranged from 0.1 to 
16.8 patients per million employed (8.5 in Finland) (2). Th is is fairly 
congruent with the incidence ﬁ gures in the mid-nineties reported here. 
We were able to estimate the incidence of CSE also in populations at risk, 
meaning to compare the number of CSE cases to the number of those 
employed in various work tasks with solvent exposure and to the number 
of workers exposed to speciﬁ c solvent groups at various exposure levels. 
Comparison of the number of CSE cases classiﬁ ed by their main solvent 
exposure with national data from FINJEM on the exposed workforce 
revealed the highest incidence in workers whose exposure had included 
aromatic hydrocarbons or solvents from the group of other organic sol-
vents or both. Th e comparison to a workforce exposed at levels >50% 
of the OEL revealed the highest incidence in workers with their main 
exposure to aliphatic hydrocarbons. Th e incidence ﬁ gures in these highly 
exposed populations are especially relevant because the exposure levels of 
all our CSE patients have exceeded 50% of the OEL. Th ese results may 
thus indicate the underrated neurotoxicity of aliphatic hydrocarbons. 
Exposure-work tasks
Th e exposure-work tasks associated with CSE in our study are very similar 
to those reported from New Zealand (8,17) and from the Netherlands 
(180). Th e most common work task of the CSE patients diagnosed in the 
1990s was painting. In the 2000s other work tasks, such as printing, ﬂ oor 
laying and lacquering, and reinforced plastic laminating, have emerged. 
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Early solvent studies focused primarily on painters, which presumably 
led to a decrease in solvent exposure in construction painting, among 
the ﬁ rst occupations aﬀ ected. As over 70% of the paints and lacquers in 
construction painting are nowadays water-soluble, the percentage used 
in industrial painting is only 10 (10,11). Th e relative increase in number 
of CSE cases in, for example, wooden-surface ﬁ nishing and industrial, 
metal, or car painting may thus reﬂ ect inadequate preventive actions and 
a need for focus on information and screening. Furthermore, younger 
age at CSE diagnosis, shorter mean DEY, and higher OELY in reinforced 
plastic lamination, with exposure predominantly to styrene, suggests an 
increased risk for CSE in this ﬁ eld.
Solvent exposure
Th e most common solvent exposure (aromatic hydrocarbons and the 
group of other organic solvents) among the CSE cases in our study is in 
line with that reported in New Zealand (8), although due to a diﬀ erent 
classiﬁ cation of solvents, so detailed comparison is unfeasible. In one of 
the cases with single-solvent exposure, the patient was exposed to ethyl 
acetate, considered to have low neurotoxicity at occupational exposure 
levels (242). In rats, however, subchronic exposure at high levels causes 
neurobehavioral disturbances (243). More attention should thus be on 
the occupational exposure levels and neurotoxic eﬀ ects of ethyl acetate; 
it was, among our 128 CSE patients, also a component in the solvent 
mixture in 28 (22%) cases.
Th e duration of occupational solvent exposure in our patients was 
almost always more than 10 years and in most cases exceeded 20. DEY of 
at least 10, also suggested by the expert group convened by the European 
Commission (187), seems to be a good practical guideline for evalua-
tion of exposure in suspicion or in diagnosis of CSE. OELY is a more 
accurate index of the neurotoxicity of solvent exposure. It seems useful 
in the diagnostics of CSE, although its estimation requires expertise in 
and detailed knowledge of working conditions, solvent exposure, and 
exposure levels. OELY is, however, a retrospective estimate relying on 
the history of life-time solvent exposure and on data for exposure levels 
in similar work tasks. It is thus prone to inaccuracy; it may under- or 
overestimate individual exposure, especially exposure peaks. Our four 
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CSE cases with OELY values between four and six indicate that the 
lower limit of six, usually considered a prerequisite for a CSE diagnosis 
at FIOH (14), should be merely a guideline. Based on our results, an 
OELY above six can be considered suﬃ  cient for the diagnosis of CSE, 
at an OELY between four and six the diagnosis is possible, and below 
four, the exposure is probably insuﬃ  cient to cause CSE. While the 
mean age and DEY of CSE patients have increased between 1995 and 
2007, mean OELY has remained unchanged, which indicates an OELY 
threshold for CSE.
Patient characteristics
Our patients’ mean age (52.8 years), as well as mean duration of exposure 
(28.4 years) was clearly higher than reported in New Zealand (mean 
age 39.0 years, mean exposure 19.8 years) (8). Th ey also found cases 
aged less than 30, whereas in our study population, no CSE appeared 
in workers aged less than 35, and most of the cases were over 45. Th e 
diﬀ erence in age and duration of exposure may on the one hand be re-
lated to the study design in New Zealand, where medical practitioners 
actively screened workers during 1993–1997, which may have led to 
earlier diagnosis at a younger age. On the other hand, higher exposure 
level may contribute to diagnosis at a younger age. Th e patients may also 
present with milder brain disease, as did 14 (18%) of the 76 presenting 
with CSE type I, which in Finland is actually not considered CSE due 
to lack of cognitive ﬁ ndings. 
Almost all the patients referred to FIOH during 2002–2004 (14 of 19; 
74%) were considered unable to work and granted a disability pension 
due to CSE. Of the ﬁ ve patients with residual work ability, four were 
ﬁ nally granted a disability pension, and only one continued in working 
life. Employment of workers with residual work ability often fails, due 
to restrictions on their solvent exposure, and cognitive disturbances 
may prevent occupational rehabilitation. To maintain solvent-exposed 
workers’ ability to work, we should intensively focus on prevention of 
excessive exposure, early detection of symptoms predicting CSE, and on 
sensitive and valid tools for early diagnostics.
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6.2 Magnetic resonance imaging
MRI is included in the diagnostic procedure of CSE at the FIOH and 
in many other centers at least in Europe, the United States, and New 
Zealand (6). Because MRI ﬁ ndings among studies have, however, been 
inconsistent, the role of MRI as a diagnostic method has been unclear.
Of 71 CSE patients, we found slight to moderate MRI abnormalities 
in 27 (38%). Th e most prevalent white matter abnormalities were small 
or large focal lesions in the deep white matter. Atrophy was most fre-
quently located in the frontal or parietal cortex, vermis, and cerebellum.
Our slight white-matter ﬁ ndings and brain atrophy are congruent 
with the results of other MRI studies on CSE patients (66,70). Findings 
of thinning of the corpus callosum and hypointensity in the basal gan-
glia in T2 -weighted images in solvent-exposed workers or CSE patients 
(70,72,74) – similar to that associated with toluene or alcohol abuse 
(26,41,42,50) – were not corroborated here. It thus remains unclear 
whether these ﬁ ndings would be explained by solvent exposure or by 
some other etiology. 
Most frequently, cerebral atrophy occurred in frontal and parietal 
brain areas. Th is is in line with the assumption of frontoparietal dys-
function in CSE which is supported by SPECT studies on solvent-
exposed workers and CSE patients (127,203,244). Furthermore, PET 
in solvent-exposed workers with cognitive dysfunction has, during a 
working-memory task, revealed frontal dysfunction (164). 
MRI studies have shown that alcohol abuse and even moderate 
alcohol consumption is associated with brain atrophy (53–55). Th is 
is observed in the cerebellum, especially in the upper vermis, and in 
the frontal white-matter. A frequent ﬁ nding is also global volume loss 
(245–247). We found an association between alcohol consumption and 
vermian atrophy but not cerebellar or cerebral atrophy. Excessive alcohol 
consumption was an exclusion criterion, but if alcohol consumption was 
under-reported, it would be impossible to totally exclude the eﬀ ects of 
alcohol on MRI ﬁ ndings. Since, alcohol (i.e. ethanol) is itself a solvent, 
similarity in brain MRI ﬁ ndings in association with alcohol abuse and 
solvent exposure would be unsurprising. 
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Brain atrophy is also associated with age (248), but we found no such 
association. Cerebral and cerebellar atrophy was, however, associated with 
duration of exposure even with age as a covariate in statistical analyses. 
Th is conﬁ rms ﬁ ndings in solvent-exposed workers of an association 
between duration of solvent exposure and brain atrophy (249). 
Most of our ﬁ ndings in the white matter were considered to be 
normal age-related changes or only slight abnormalities. In a normal 
healthy population, age-related white matter hyperintensities become 
increasingly apparent after age 50 (250), and we found an association 
between periventricular and brainstem white matter hyperintensities and 
age. As we lacked a control group, it is diﬃ  cult to conclude whether or 
not CSE patients have more brain MRI abnormalities, atrophy, or white 
matter changes than do healthy non-exposed subjects of the same age.
Most (62%) brain MRI scans of our CSE patients were classiﬁ ed as 
normal. Our percentage of abnormal MRI was much lower (38%) than 
in earlier MRI studies (70% – 100%) (66,70). Th is diﬀ erence may be 
due to the thorough diagnostic and diﬀ erential diagnostic procedure and 
follow-up at FIOH, and strict criteria in the MRI study to exclude cases 
with confounding etiologies. Moreover, as we wanted to avoid overesti-
mation of the MRI abnormalities, the ﬁ nding was considered positive 
only if both neuroradiologists agreed; if disagreement occurred, the lower 
rating was chosen. Visual rating is always subjective, and interobserver 
variability increases as the ﬁ ndings diminish. Accuracy of evaluation of 
brain atrophy can be improved by volumetric methods. Visual evaluation 
is, however, the method used in clinical practice. Our study, as any other 
previous studies, revealed no speciﬁ c MRI ﬁ ndings in CSE. Judgment as 
to the presence and etiology of MRI ﬁ ndings in cases with a suspicion 
of CSE should be cautious: In cases with major abnormalities in brain 
MRI, non-solvent etiologies deserve consideration. 
6.3 Quantitative electroencephalography
QEEG in CSE patients – compared to that in laboratory controls – re-
vealed an increase in absolute frontal theta power indicating neuronal 
dysfunction in frontal areas. In the study of  Ørbæk et al, increased theta 
power appeared in all brain areas of CSE patients, although the relative 
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increase in absolute theta power was most prominent in frontal areas 
(132). Th is diﬀ erence may be explained by a milder brain disorder in 
our patients (diagnosis in the 1990s) due to lower exposure levels than 
the levels for patients of the previous study (diagnosis in the 1970s). 
Th e laboratory controls in our study were younger, but age was con-
trolled for in the statistical analyses and did not interfere with the results. 
As the laboratory controls, recruited from the staﬀ  of FIOH, were prob-
ably better educated than the patients, we used another control group, 
comprising age-matched blue-collar workers of the same socio-economic 
and educational level as the CSE patients. 
In comparison with CSE patients, these matched controls presented 
with increased beta power in their temporal areas. Compared to the labo-
ratory control group, absolute frontal theta power was increased in the 
age-matched control group almost as much as in the CSE patient group 
(1.5 versus 1.6 times), and beta power was increased in all except occipital 
areas. In conditions of reduced cognitive processing capacity such as in 
aging and in pathological conditions such as in alcohol encephalopathy 
and Alzheimer’s disease, theta frequency increases (123,124). In the 
original study of Portin et al, one-ﬁ fth of the matched controls presented, 
however, with mild cognitive impairment on cognitive tests (228). Th e 
authors stated that “the causes of this impairment and possible incipient 
cerebral dysfunction were not easily recognizable on the basis of health 
data or employment status and thus remained unexplained” (228). We 
did not, however, ﬁ nd any association between cognitive scores and 
EEG ﬁ ndings.
Th e increase in total or beta power seen in solvent-exposed workers 
and CSE patients (69,115,116,130,132–134) remained unconﬁ rmed 
here. Increased beta power, as well as increased frontal theta power, as-
sociates with alcohol abuse and also with moderate alcohol consumption 
(125,251). Interestingly, the only characteristic diﬀ erence was in alcohol 
consumption between matched controls (381.2 grams absolute alcohol / 
month) and CSE patients (205.2 grams). We found, however, no asso-
ciation between theta or beta power and alcohol consumption in the 
patient or matched control groups. Excessive alcohol consumption was 
an exclusion criterion in our study, but data on alcohol consumption in 
the matched control group was based on a self-administered question-
naire, which may be vulnerable to underestimation and underreporting 
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(252). In CSE patients, assessment of alcohol consumption, based on a 
detailed interview, clinical examination, and previous medical records, 
was strict and thus more reliable. 
Our QEEG ﬁ ndings reﬂ ect cognitive dysfunction in the CSE patients 
and suggest that the frontal cortex is more susceptible than other brain 
areas to the neurotoxic eﬀ ects of solvents. Th is is in line with our brain 
MRI ﬁ ndings of the most frequent brain atrophy in frontal and parietal 
areas. Because the ﬁ ndings in QEEG were slight and non-speciﬁ c, and 
only 11% of the QEEG recordings were originally interpreted as abnor-
mal, QEEG cannot be recommended in the diagnostics or diﬀ erential 
diagnostics of CSE. 
6.4 Event-related potentials
Single-task condition
Th e main result in the auditory ERP study was that – in comparison 
with laboratory and age-matched controls – CSE patients have de-
creased auditory P300 amplitudes at Pz. Th is ﬁ nding was conﬁ rmed 
in the multimodal ERP study. Th is result parallels ﬁ ndings in a small 
CSE patient group very similar to ours in age, exposure, and education 
(134); although in other studies on CSE patients, P300 amplitude has 
been normal but latency prolonged (145,146). Findings of decreased 
amplitudes and prolonged latencies in visual tasks in CSE patients and 
solvent-exposed workers (113,114) were not corroborated here, perhaps 
related to diﬀ erences in study populations or in ERP paradigms. In 
auditory tasks, the paradigm most commonly used is the standardized 
oddball paradigm which enables comparisons between ERP studies. In 
contrast, the visual paradigms applied are much more variable. 
Findings of prolonged P300 latency in solvent-exposed workers and 
CSE patients (69,120,145,146) were in part corroborated in the audi-
tory ERP study. CSE patients had longer P300 latencies than did our 
laboratory control group but not longer than our age- and education-
matched controls. Prolonged P300 latency associates with increasing age 
(157). Th e younger age of the laboratory controls does not, however, 
explain this diﬀ erence, as age was controlled for in the statistical analy-
ses. Alcohol consumption also associates with prolonged P300 latency 
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(124,140). Th e higher alcohol consumption of the age- and education 
matched control group than that of the patients may thus explain the 
diﬀ erences in latency values. In the multimodal ERP study, latencies did 
not diﬀ er between CSE patients and age-matched controls with equal 
alcohol consumption. Nor did we ﬁ nd any association between P300 
amplitude or latency and the amount of reported alcohol consumption.
Diﬀ erences in ERP results between ours and earlier studies’ may be 
related to diﬀ erences in study populations. Moreover, whereas most of 
those studies included solvent-exposed workers without a deﬁ nite CSE 
diagnosis, our cases, carefully examined CSE patients meeting strict 
exclusion criteria, produced more reliable results.
Major depression has been shown to be associated with decreased 
auditory P300 amplitude and prolonged latency (139). We found no 
such association in the auditory ERP study, in which we used the DSM-
IV diagnostic criterion in retrospective psychiatric re-evaluation of psy-
chiatric medical records. Th is is in line with a ﬁ nding of no association 
in CSE patients between amplitude or latency and Beck Depression 
Inventory (BDI) scores (145). In the multimodal ERP study, depression 
was excluded by DEPS. Serotonin reuptake inhibitors, benzodiazepine 
derivates, and medication with anticholinergic eﬀ ects are also associ-
ated with decreased P300 amplitude (253–255), but we found no such 
association. 
During the follow-up period of on average 14 months (range 10–18) 
in the auditory ERP study, changes in P300 values at group level were 
non-signiﬁ cant. One study showed that in solvent-exposed workers, 
longer time from exposure to test associates with improved P300 latency 
(256). We found a tendency for improvement in P300 amplitude, al-
though individual changes in P300 amplitude are diﬃ  cult to interpret 
due to large intraindividual variability (135). Th e follow-up results sug-
gest, however, that removal from solvent-exposure work may improve 
cognitive processing or at least prevent further deterioration of the brain 
dysfunction in CSE patients, as the ERP results in most of the patients 
(11 of 19) remained unchanged. 
Length of exposure was correlated with P300 latency in one small 
group of 12 CSE patients (145). In our auditory ERP study, as in the 
QEEG study, the results did not correlate with exposure indices. Th is 
lack of correlation may be related to inaccuracy in assessing exposure, 
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especially peak exposures. Furthermore, individual susceptibility to the 
neurotoxic eﬀ ects of solvents varies, due to several factors such as in-
dividual diﬀ erences in toxicokinetics and metabolism of solvents (28), 
which in clinical studies are very diﬃ  cult to control. 
Based on the laboratory’s reference values, all the individual P300 
amplitude values of the CSE patients and the matched controls in the 
auditory ERP study were classiﬁ ed as normal (i.e., age corrected mean 
± 2.5 SD). Th e latencies were classiﬁ ed as abnormal in 30% of the CSE 
patients and in 26% of the matched controls. Th e diﬀ erence in sensitivity 
between amplitude and latency may be due to the larger interindividual 
variability in amplitude values. 
Dual-task conditions 
Th e original hypothesis of the multimodal ERP study was that the de-
crease in amplitude with increasing task demands would be more marked 
in CSE patients than in controls. Th is was in part conﬁ rmed. Th e change 
between the groups in mean auditory P300 amplitudes between AUD, 
AUD+VIS, and AUD+MEM conditions did not diﬀ er. Th e auditory 
P300 in the dual-task condition was, however, unrecognizable more 
frequently in patients than in controls.
P300 amplitude is sensitive to the amount of attentional resources 
engaged in task performance. Decreased amplitude reﬂ ects insuﬃ  cient 
allocation of attentional resources during task processing, and decreased 
brain activity required in the maintenance of working memory (140), i.e., 
cognitive processes is typically disturbed in CSE (148,149,151–153). In 
dual-task conditions, meaning concurrent requirements to hold informa-
tion in working memory or when multiple tasks compete for attention, 
an increase in the diﬃ  culty of the primary task leads to a decrease in the 
resources available for the secondary task; thus the amplitude from the 
secondary task decreases (137,257). Stimuli that would normally elicit 
P300 fail to do so if they are ignored or if attention is directed elsewhere 
(257). Th e subjects in our study were not, however, instructed to pay 
attention either to auditory or visual stimuli. ERP results in the dual-
task condition suggest that CSE patients have diﬃ  culties in updating 
information and in dealing eﬀ ectively with an increase in processing 
load, due to impaired ability to allocate attentional resources and to shift 
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attention between two tasks. Similar disturbances can be seen in patients 
with Parkinson’s disease (258).
Th e duration of the test session in the multimodal ERP study was 
rather long (about 60 to 90 minutes). Fatigue and a decreased state of 
arousal during the task performance impair vigilance, i.e., the ability to 
maintain attention and alertness over prolonged periods of time, which 
then aﬀ ects ERP responses. As the dual-task condition with the highest 
cognitive processing load (AUD+MEM) was performed in the middle of 
the test session before the AUD+VIS condition, decreased state of arousal 
does not seem to explain the impaired ERP responses in dual- versus 
single-task conditions. During the test session, the research technician 
noted the subjects’ alertness. Furthermore, the subjects’ performance in 
Rapid Visual Information Processing (RVP) – an analogy to the Con-
tinuous Performance Task (CPT), requiring sustained attention (234) 
– which was performed immediately after the ERP recording as a part 
of the neuropsychological test battery, was not impaired, thus reﬂ ecting 
a normal state of arousal.
In dual-task conditions, the amplitude was decreased or the response 
absent to auditory but not to visual stimuli, which indicates asymmetry 
in the allocation of attentional resources. Th is may be explained by the 
visual dominance theory: when visual and auditory signals are presented 
simultaneously, subjects generally respond to the visual stimulus and 
may even be totally unaware of the auditory stimulus (259). Divided 
attention causes impairment more in auditory than in visual stimulus 
evaluation (260). One hypothesis states that visual stimuli are less alert-
ing and need to be processed actively, whereas auditory stimuli have an 
automatic alerting eﬀ ect (261). More attentional resources are thus al-
located to the visual stimulus, which contributes to the higher amplitude 
values for visual than auditory stimulus, also seen in the multimodal 
ERP study (260,261). 
Task performance
P300 latency is a measure of cognitive processing speed suggested to 
represent the time required for stimulus evaluation but not for response 
selection (137,262). Reaction time reﬂ ects information processing in-
cluding stimulus perception, comparison of the current stimulus with the 
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target in the memory, and selection of the appropriate response, followed 
by execution of that response (262). Prolonged RT in CSE patients to 
auditory stimuli in both dual conditions and to visual stimuli in the 
AUD+VIS condition without any increase in latency may thus reﬂ ect 
deﬁ cits in the later phases of information processing, i.e., in selection of 
the correct response or in the initiation and execution of the response 
after stimulus identiﬁ cation. When task diﬃ  culty increased, the diﬀ er-
ence in RT between our patients and controls disappeared, which may 
indicate a ceiling eﬀ ect and the fact that the ERP paradigm was too dif-
ﬁ cult. Slower performance speed in the patient group may also account 
for their inferior, although statistically insigniﬁ cant, response accuracy, 
because after 2000 ms any response was considered a miss. Furthermore, 
presentation of the subsequent stimuli within the response window of 
the previous stimuli impairs response accuracy.
Th e association found between prolonged P300 latency in CSE pa-
tients and impaired cognitive tests scores, especially in tasks requiring 
attention (263), was not corroborated here. In the auditory ERP study, 
our three neuropsychological tests measured various aspects of attention 
and short-term memory (Digits forward, Digits backward, and Digit 
symbol substitution). Digit symbol substitution correlated positively 
with P300 amplitude both in the patient and in the matched control 
group. Th is is unsurprising, as P300 amplitude reﬂ ects the eﬃ  cacy of 
information processing and allocation of attentional resources, and Digit 
symbol substitution is a complex time-limited task requiring focused, 
sustained, and shifted attention with demands on visuomotor coordina-
tion and psychomotor speed (264, 265).
In the multimodal ERP study, we found no correlation between 
neuropsychological test results and ERP values. Th is indicates that the 
ERP paradigm measures diﬀ erent aspects of cognitive processing than 
do the neuropsychological tests we applied. Furthermore, surprisingly 
few statistically signiﬁ cant diﬀ erences in neuropsychological test results 
emerged between patients and controls, especially when taking into ac-
count the higher mean education of those controls. Th is may be due to 
the small size of the study group and the large variation in test results 
especially in the patient group. Th e retest eﬀ ect may also contribute to 
the results (148), as half the patients were familiar with the cognitive 
tests. Th is strengthens, however, the result showing a signiﬁ cant diﬀ er-
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ence between patients and controls in the performance of Intra-Extra 
Dimensional Set Shift (IED). IED is analogous to the Wisconsin Card 
Sorting Test (WCST) and requires shifting and ﬂ exibility of attention, 
attentional set formation maintenance, and visual discrimination (234). 
PET and fMRI studies have shown that WCST activates the dorsolat-
eral and ventrolateral prefrontal cortex and caudate nucleus, regions 
important for the set-shifting process and working memory functions 
(266,267). WCST is sensitive to changes in the fronto-striatal areas and 
is typically impaired in patients with Parkinson’s disease (234). Spatial 
Working Memory (SWM), which requires the ability to retain spatial 
information and to manipulate remembered items in working memory, 
is a sensitive measure of frontal lobe and executive dysfunction. Th e 
strategy score in SWM is typically lower in patients with frontal brain 
dysfunction. Th e unimpaired performance of CSE patients in SWM and 
especially high strategy scores may indicate that the cognitive deﬁ cits in 
CSE are related to disturbances not in the frontal brain area but in pos-
terior aspects of frontoparietal continuity. Th is assumption is supported 
by our ﬁ nding of decreased auditory P300 amplitude in CSE patients 
in Pz but not at Fz. Th is indicates a posterior disturbance in the neural 
generators of P300 which involves the widespread cortical network in 
the prefrontal and parietal cortex, medial temporal complex, and areas 
of the temporoparietal junction (137,268,269). Interestingly, in aging, 
accompanied by slowed information processing and a decline in working 
memory and in attentional abilities, P300 amplitude also decreases in 
parietal but not in frontal areas (157,165). 
6.5 Strengths and limitations of the study 
Th e material of Study I, which was based on comprehensive data sources 
(clinical patient records at FIOH, FIOH’s Register of Industrial Hygiene 
Measurements, FINJEM, and Statistics Finland), is unique. Furthermore, 
because the diagnostics of CSE is nationally centralized in the FIOH, 
the numbers of annually diagnosed cases are inclusive and match the 
ﬁ gures of the Finnish Register of Occupational Diseases. 
Th e numbers of exposed workers at diﬀ ering exposure levels were 
gathered from FIMJEM. Th e deﬁ nition of occupations and agents in 
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FINJEM limits, however, its use because all workers with the same oc-
cupational title are assigned to the same class, irrespective of their actual 
exposure status or level (235,270). Furthermore, most patients (92%) 
had been exposed to mixtures of solvents at variable exposure levels. 
Misclassiﬁ cation of exposure may thus skew the number of exposed 
workers and lead to incidence-ﬁ gure unreliability. 
Being based on thorough diagnostic procedures at FIOH, includ-
ing detailed analyses of solvent exposure, multidisciplinary diﬀ erential 
diagnostics, and follow-up, the study material is well-characterized, and 
the CSE diagnosis of all the patients in the ﬁ ve studies is highly reliable. 
Moreover, the study group of 71 patients in Study II (MRI) and 86 
patients in Study IV (auditory ERP) were exceptionally large compared 
to previous MRI studies on 9 to 32 patients (66,70) and ERP studies 
on 12 to 20 patients (134,145). Th e limitation of Study V (multimodal 
ERP) is the small size of the study group, because of the 26 patients 
contacted, only 11 were included. Th is study was, however, basically a 
pilot study designed to test the multimodal ERP paradigm.
In the MRI study, we used standard images to assess brain atrophy 
and a validated classiﬁ cation scale to evaluate white matter ﬁ ndings, 
which has not been done in other CT or MRI studies on solvent-exposed 
workers or CSE patients. A limitation of the study is, however, lack of 
any control group. It is especially troublesome if the ﬁ ndings are slight 
and non-speciﬁ c, as in our study. As both atrophy and white matter 
changes increasingly appear with aging, the association of MRI ﬁ ndings 
and solvent exposure remains indeﬁ nite. 
ERPs are inﬂ uenced by several factors (such as circadian rhythm, 
fatigue, personality, genetic factors) which are diﬃ  cult to control in 
clinical studies (140). Because patient characterization in Study IV was 
based on clinical patient records, a validated questionnaire on depression 
was unavailable. Depression at the time of ERP recording was assessed 
by analysis of the clinical psychiatric patient records by a psychiatrist; 
this makes the diagnosis of major depression reliable. Data on occasional 
medication, such as sleeping pills, and alcohol consumption during the 
day preceding ERP recordings was unavailable and thus, their acute ef-
fects on CNS and ERP cannot be totally excluded. Smoking, which also 
aﬀ ects ERP (142), was disregarded in the analyses. Th e diﬀ erent methods 
in assessing alcohol consumption in the patient group (a questionnaire 
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and an interview) and in the control group (a questionnaire) may have 
inﬂ uenced the amount of reported alcohol consumption and thereby the 
QEEG and ERP results. To study the explanatory eﬀ ects of confounding 
etiologies in Study IV, we could have used regression analyses. 
Comparison of the QEEG and auditory ERP results between matched 
controls and laboratory controls revealed signiﬁ cant diﬀ erences. We chose 
the age- and education-matched control group of blue-collar workers in 
order to study purely the solvent eﬀ ects on EEG and ERP. Th e laboratory 
control group was based on the laboratory’s reference material on pre-
sumably healthy subjects recruited mainly from the staﬀ  of FIOH. Data 
on their alcohol consumption, smoking, medication, mood disorders, 
and education was unavailable. We included, however, the laboratory 
control group in the QEEG and ERP studies, because that is the refer-
ence material used in clinical practice. Th e fact that QEEG and ERP 
results strongly depend on the selection of control material weakens the 
reliability and sensitivity of these methods. 
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1. In Finland, the number and incidence of CSE cases during 1995–2007 
has declined. CSE aﬀ ects most probable male spray painters aged over 45 
when the duration of occupational solvent exposure mainly to aromatic 
hydrocarbons exceeds 20 years. 
2. CSE is associated with brain atrophy which correlates with duration 
of exposure. Th e atrophy and white matter MRI ﬁ ndings in CSE are, 
however, slight and non-speciﬁ c, which makes MRI in clinical practice 
useful mainly in the diﬀ erential diagnostics of CSE. In other words, if 
major abnormalities appear in the brain MRI of a patient with suspected 
CSE, non-solvent etiologies may be implicated. 
3. QEEG in CSE patients may reveal slight abnormalities. As the ﬁ ndings 
are non-speciﬁ c, QEEG is not recommended for the clinical diagnostics 
of CSE. 
4. In CSE, the P300 amplitude of auditory ERP is decreased. Th e clas-
sical oddball paradigm is, however, insensitive at an individual level and 
ineﬀ ective in clinical practice. 
5. Th e multimodal ERP paradigm seems to provide a more sensitive, 
although still non-speciﬁ c, method for individual diagnostics. Th e results 
in the multimodal ERP study indicate that CSE patients present with 
slowed performance speed and deﬁ cits in the allocation of attentional 
resources and in shifting attention, especially when the cognitive load 
increases. Th ese results also suggest a posterior disturbance in the fron-
toparietal continuity in CSE. 
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During recent decades, the number of solvent-exposed workers 
and solvent exposure in many work tasks has diminished. This 
has led to a decrease in the number of occupational chronic 
solvent encephalopathy (CSE) patients, but still every year reveals 
new cases. 
This book presents the incidence of CSE in Finland during 
1995–2007 and the work tasks and solvent exposure related to 
CSE. It also presents the findings in brain magnetic resonance 
imaging, electroencephalography, and event-related potentials 
and discusses their diagnostic value in CSE. 
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